

## Curriculum Vitae

### **Branimir I. (Brandy) Sikic, M.D.**

#### **PERSONAL DATA:**

Date of Birth: October 18, 1947  
Place of Birth: Graz, Austria  
Citizenship: U. S. A., naturalized 1962  
Marital Status: Married, three children

#### **EDUCATION AND TRAINING:**

1968 B. S. (Biology, Fine Arts), Georgetown University, Washington, DC  
1972 M. D., University of Chicago School of Medicine, Chicago, IL  
1972-75 Intern and Resident in Internal Medicine, Georgetown University Hospital  
1975-77 Research Associate, Drug Interactions Section (Dr. Theodore Gram), Developmental Therapeutics Program, National Cancer Institute, NIH, Bethesda, MD  
1978-79 Medical Oncology Clinical Fellow, Georgetown University Hospital

#### **ACADEMIC APPOINTMENTS:**

1977-78 Investigator, Drug Interactions Section, Developmental Therapeutics Program, National Cancer Institute, NIH, Bethesda, MD  
1979-86 Assistant Professor of Medicine (Oncology and Clinical Pharmacology), Stanford University School of Medicine, Stanford, CA  
1986-87 Visiting Scientist, Molecular Biology Laboratory (Dr. George Stark), Imperial Cancer Research Fund, London, England,  
1986-96 Associate Professor of Medicine (Oncology and Clinical Pharmacology), Stanford University School of Medicine  
1992-93 Associate Program Director, General Clinical Research Center, Stanford University School of Medicine and Stanford University Hospital  
1993-2008 Program Director, General Clinical Research Center, Stanford University School of Medicine and Stanford University Hospital  
1997-present Professor of Medicine (Oncology and Clinical Pharmacology), Stanford University School of Medicine  
1998-2004 Director, Cancer Clinical Trials Office, Stanford University Medical Center  
2009-2013 Associate Director for Clinical Research, Stanford Cancer Center  
2008 - 2015 Director, Clinical and Translational Research Unit, Stanford University Center for Clinical and Translational Education and Research (Spectrum)  
2008 - 2018 Co-Director, Stanford University Center for Clinical and Translational Education and Research (Spectrum)  
2015 – 2018 Medical Director, Clinical and Translational Research Unit, Stanford University Center for Clinical and Translational Education and Research (Spectrum)

#### **MILITARY SERVICE:**

Commissioned Corps, United States Public Health Service (USPHS), Surgeon-04, 1975-78  
Inactive Reserve Officer, Surgeon-04, USPHS, 1978-1990

**HONORS:**

Fellow, American Society of Clinical Oncology (FASCO), 2012  
Presidential Medal for Science and Medicine, Order of the Morning Star Katarina Zrinska, Government of Croatia, 2010  
Statesman Award, American Society of Clinical Oncology (ASCO), 2010  
Best Doctors in America, 2002-16  
John H. Blaffer Visiting Professor, M. D. Anderson Cancer Center, 2003  
Oncology Teaching Award, Stanford University School of Medicine, 2000  
Plenary Lecturer, Netherlands Cancer Institute Symposium, Amsterdam, 1999  
Plenary Lecturer, Federation of European Biology Societies (FEBS) Course on ABC Transporters, Gösau, Austria, 1997  
70th Anniversary of the CRC Lecturer, British Association of Cancer Research, London, 1993  
Pfizer Visiting Professor in Clinical Pharmacology, Dartmouth Medical School, 1992  
Warren J. Schneider Memorial Lecturer, University of the Pacific, 1990  
Faculty Development Award in Clinical Pharmacology, Pharmaceutical Manufacturers Association Foundation, 1981-83

**PROFESSIONAL SOCIETY MEMBERSHIPS:**

American College of Physicians  
American Association for Cancer Research  
American Society of Clinical Oncology  
American Society of Hematology  
American Federation for Clinical Research  
Cancer Molecular Therapeutics Research Association, Board of Directors, 2011 to present  
Western Society for Clinical Investigation  
Western Association of Physicians

**CERTIFICATIONS AND LICENSURE:**

Diplomate, National Board of Medical Examiners, 1973  
Diplomate, American Board of Internal Medicine, 1975  
Diplomate, Medical Oncology, American Board of Internal Medicine, 1979, recertified 2010  
Medical License, State of California, 1979-present

**ACTIVE GRANT SUPPORT:**

Forty Seven, Inc., "A first-in-human phase I dose escalation trial of Hu5F9-G4 in patients with advanced solid malignancies." Principal Investigator, 05/01/2016 – 5/31/19.  
Genentech, Inc., "A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Vemurafenib (RO5185426) Adjuvant Therapy in Patients with Surgically Resected, Cutaneous BRAF-Mutant Melanoma at High Risk for Recurrence," Principal Investigator for Stanford University, 07/31/2013 - 02/28/2022.

**PAST GRANT SUPPORT (partial listing):**

**Federal and Other Non-Industry:**

NIH R01 CA 184968, "New Biomarkers and Pathways to Enhance Cure by Platinum/Taxane Therapy in Ovarian Cancers." Principal Investigator, 04/01/2014 - 10/31/2018.

- NIH UL1 TR001085, "Stanford Center for Clinical and Translational Education and Research (Spectrum)." This grant is the CTSA (Clinical and Translational Science Award) at Stanford. Co-Principal Investigator, 10/1/13 – 04/30/18
- NIH U10 CA 180816, "Stanford University NCTN – Network Lead Academic Site." This application is in response to RFA CA12-013 for participation by the Stanford Cancer Center in the NCI National Clinical Trials Network – Network Lead Academic Participating Sites (U10). Co-Principal Investigator, 03/01/14 – 02/28/19.
- NIH P30 CA124435, Cancer Center Support Grant. Leader, Developmental Therapeutics Group, 06/04/07-05/31/14.
- NIH UL1 RR 025744, "Stanford Center for Clinical and Translational Education and Research (SCCTER)." CTSA Award, Co-Principal Investigator, 05/19/2008 - 09/30/2013.
- NIH R01 CA 114037, "Taxane Resistance in Breast and Ovarian Cancer Cells." Principal Investigator, 08/01/2007 - 04/30/2013.
- NIH R01 CA 92474, "Regulation of the Human *MDR1* Gene." Principal Investigator, 04/01/2002 – 03/31/2007.
- NIH R01 CA 90916, "Genomic Profiling of Childhood De Novo and Relapsed AML." Co-Investigator (G. Dahl, P. I.), 04/01/2001 – 03/31/2007.
- NIH R33 CA 89830, "Gene Expression Profiling of Unknown Primary Cancers." Principal Investigator, 04/01/2001 – 03/31/2006.
- NIH R01 CA 52168, "Modulation of Multidrug Resistance Mechanisms." Principal Investigator, 06/01/1990 – 05/31/2003.
- NIH M01 RR-00070, "General Clinical Research Center." Program Director, 12/01/1992 - 05/31/08.
- NIH R01 CA 68217, "Tubulin Genes and Drug Resistance." Principal Investigator, 05/01/1996 – 05/31/2000.
- NIH R01 CA 42417, "Morpholino Anthracyclines." Principal Investigator, 08/01/1986 – 07/31/1989.
- NIH R01 CA 33303, "Cellular Pharmacology of Anthracyclines in Human Cancers." Principal Investigator, 07/01/1982 – 06/30/1985.
- NIH R01 CA 27478, "Bleomycin Pharmacology and Toxicology." Principal Investigator, 08/01/1979-01/31/1983.
- California Institute for Regenerative Medicine (CIRM). Weissman, I. (P.I.) "Clinical Investigation of a Humanized Anti-CD47 Antibody in Targeting Cancer Stem Cells in Hematologic Malignancies and Solid Tumors." Co-investigator, 04/01/2014 - 05/18/2016. Dr. Sikic is the PI of the Phase I Trial of Hu5F9-G4 in Solid Tumors.
- Department of Defense DAMD17-03-1-0239, "Mechanisms of Taxane Resistance in Ovarian Carcinomas." Principal Investigator, 04/01/2003 –03/31/2007.
- Department of Defense DAMD17-94-J-4352, "Paclitaxel (Taxol) Resistance in Breast Cancer Cells." Principal Investigator, 10/01/1994 –09/30/1998.
- American Cancer Society RPG-88-005-11-CDD, "Multidrug Resistance in Human Cancer Cells." Principal Investigator, 07/01/1997 - 06/30/2001.
- American Cancer Society DHP-76, "Multidrug Resistance in Human Cancer Cells." Principal Investigator, 07/01/1993 - 06/30/1997.
- American Cancer Society CH-411, "Multidrug Resistance in Human Cancer Cells." Principal Investigator, 01/01/1988 - 06/30/1993.
- American Cancer Society CH-323, "Multidrug Resistance in Human Cancer Cells." Principal Investigator, 01/01/1985 - 06/30/1993.

California Cancer Research Program, State of California, "Genomic Profiling of Ovarian Cancer." Principal Investigator, 01/01/1999 – 12/31/2001.

**Industry:**

Basilea Pharmaceutica International Ltd., "Determinants of Sensitivity and Resistance to Basilea Pharmaceutics International Ltd. Investigational Compound BAL27862." Principal Investigator, 09/01/2010 - 06/30/2018.

Sanofi-Aventis, "Distinguishing cabazitaxel activity from first generation taxanes." Principal Investigator, 10/15/2014 - 10/14/2018

Celldex Therapeutics, "A Phase I/II Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-CD27 antibody (Varlilumab) Administered in Combination with Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors." Principal Investigator, 12/09/2015 – 11/30/2018.

Gilead Sciences, "SYK Inhibition by Entospletinib in Ovarian Cancers." Principal Investigator, 01/01/2016 – 12/31/2017.

Celldex Therapeutics, Inc., "A Phase I, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients with Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors," Principal Investigator, 11/15/2012 – 11/30/2015.

Novartis, "CMEK162A2301: The NEMO trial (NRAS melanoma and MEK inhibitor): A Randomized Phase III, Open Label, Multicenter, Two-Arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-Positive Melanoma." Principal Investigator, 2/27/2013 – 3/31/2016.

Exelixis, Inc., "A Randomized Discontinuation Study of XL184 in Subjects with Advanced Solid Tumors." Principal Investigator, 07/01/2010-06/13/2013.

Human Genome Sciences, Inc., "A Phase I, dose escalation study to evaluate the safety and tolerability of AEG40826.2HC1 in patients with advanced solid tumors." Principal Investigator, 05/30/2008 - 05/29/2013.

OncoMed Pharmaceuticals, Inc., "A Phase I, Dose Escalation Study of OMP-21M18 in Subjects with Solid Tumors." Principal Investigator, 02/06/09 – 06/30/13.

Amgen, Inc., "A Phase 1b/2 Open Label, Dose Escalation Study of AMG 655 in Combination with AMG 479 in Subjects with Advanced, Refractory Solid Tumors." Principal Investigator, 10/27/09 – 09/30/13.

Johnson & Johnson, "CCL2 Blockade as a Therapy in Ovarian Cancers." Principal Investigator, 08/01/2010-7/29/2013.

Genentech, Inc., "A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of GDC-0973/XL518 Administered Orally Daily to Subjects with Solid Tumors – MEK4592g." Principal Investigator, 05/15/08-03/31/13.

Hoffmann-La Roche, Inc./Genentech, Inc./Plexxikon, Inc., "Protocol NP25163: A Phase I, randomized, open-label, multi-center, multiple dose study to investigate the pharmacokinetics and pharmacodynamics of RO5185426 administered as 240 mg tablets to previously treated BRAF V600E positive metastatic melanoma patients." Principal Investigator, 9/1/2010-11/15/2012.

AstraZeneca, Inc., "A Phase I Trial of ZD6474 [Vandetanib] Combined with Capecitabine and Oxaliplatin (XELOX) and Bevacizumab for the First-Line Treatment of Metastatic Colorectal Cancer." Principal Investigator, 07/06/2006 – 06/30/2010.

Bristol-Myers Squibb Inc., "Determinants of Response to Microtubule Stabilizing Drugs." Principal Investigator, 07/01/2007 – 12/31/2008.

- Bristol-Myers Squibb, Inc., "A Phase I Study of Ixabepilone Administered as 3 Oral Doses Each Separated by 6 Hours Every 21 Days in Subjects with Advanced Cancer." Principal Investigator, 05/15/08 – 07/15/09.
- Sanofi-Aventis, Inc., "Mechanisms of Resistance to XRP6258 and XRP9881 in Breast and Ovarian Cancer Cell Lines." Principal Investigator, 06/01/06 – 05/31/08.
- Rhone-Poulenc Rorer Pharmaceuticals, Inc., "Taxotere Resistance in Human Breast and Ovarian Cancers." Principal Investigator, 01/01/1999 – 12/31/2000.
- Basilea Pharmaceutica AG, "Sensitivity of Basilea Pharmaceutica Investigational Compound BAL27862 in MDR1/ABCB1(-) Taxane-Resistant Human Breast and Ovarian Cell Models." Principal Investigator, 01/01/2009 - 09/30/2009.
- Symphony Evolution, Inc., "XL647-002: A Phase I Dose-escalation Study of the Safety and Pharmacokinetics of XL647 Administered Orally daily to Subjects with Solid Tumors." Principal Investigator, 07/25/2006 - 8/31/2010.
- Exelixis Pharmaceuticals, Inc., "A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL518 Administered Orally Daily to Subjects with Solid Tumors." Principal Investigator, 07/12/2007 - 07/11/2009.
- Exelixis Pharmaceuticals, Inc., "A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL647 Administered Orally to Subjects with Solid Tumors." Principal Investigator, 05/11/2004 - 04/18/2007
- Human Genome Sciences, Inc., "A Phase I, Multi-center, Phase I Trial of HGS-ETR2 (Fully-Human Monoclonal Antibody to the Trail-R2) in Subjects with Advanced Solid Malignancies." Principal Investigator, 02/26/2004 - 02/25/2007.
- Human Genome Sciences, Inc., "A Multi-Center, Phase I Trial of HGS-ETR2 (HGS1018, a Fully Human Monoclonal Antibody to TRAIL-R2) in Combination with Gemcitabine, Pemetrexed, Doxorubicin, or Folfiri In Subjects with Solid Malignancies." Principal Investigator, 03/29/06 - 2003/31/2008.
- Isis Pharmaceuticals, Inc., "Phase I/II Trials of an Antisense Inhibitor of PKC-a." Principal Investigator, 08/01/1997 - 07/31/2000.
- Lilly Research Laboratories, Inc., "A Phase 1 Dose Escalating Study of LY335979 in Combination with Mitoxantrone in Patients with Hormone-Refractory Prostate Cancer." Principal Investigator, 11/01/98 – 04/30/2000.
- Bristol-Myers Squibb, Inc., "Phase I Study of BMS-310705 Given Every Three Weeks in Patients with Advanced Solid Malignancies," Principal Investigator, 03/01/02 - 12/31/03.
- Bristol-Myers Squibb, Inc., "Phase I Study of BMS-188797 Administered on Day 1 and Day 8 Every 21 Days in Patients with Advanced Solid Malignancies," Principal Investigator, 03/01/00 - 12/31/01.
- Sandoz, Inc., "A Phase II Study of Paclitaxel and PSC 833 in Metastatic Colorectal Carcinoma," Principal Investigator, 06/01/96 - 05/31/98.

#### **PATENTS:**

- United States Patent #5,830,697; Issued Nov. 3, 1998, "P-Glycoprotein Mutant Resistant to Cyclosporin Modulation"
- United States Patent #7,875,274; Issued January 25, 2011, "Protein Modulators of Resistance to Alkylating Agents"

#### **UNIVERSITY AND HOSPITAL COMMITTEES:**

- Executive Committee, Stanford Center for Clinical and Translational Education and Research (SPECTRUM), 2008-2018

Advisory Committee, *Ex Officio*, Clinical and Translational Research Unit, Stanford University School of Medicine, 2008-2018  
Member, Developmental Therapeutics Clinical Research Group, Stanford University Cancer Center, 2014-present  
Oncology Division UTL Faculty Search Committee, 2012-present  
Oncology Division Chief Search Committee, Stanford Department of Medicine, 2011-12  
Research Space Planning Committee, Stanford Department of Medicine, 2008-09  
Nephrology Faculty Search Committee, Stanford Department of Medicine, 2007-08  
Scientific Review Committee, Stanford Cancer Center, 2007-2013  
Clinical Research Planning Committee, Department of Medicine, 2004-06  
Chair, Research Policy Review Committee for HIPAA, Stanford University School of Medicine, 2002-03  
Translational Research Planning Committee for the School of Medicine, 2002-2005  
Oncology Informatics Steering Committee, Stanford University School of Medicine, 2002-5  
Appointments and Promotions Committee, Department of Medicine, Stanford University School of Medicine, 1999-2003  
Steering Committee, Clinical Cancer Center, Stanford University Medical Center, 1998-2004  
General Clinical Research Center Advisory Committee, Stanford University School of Medicine, 1992-2008 (ex officio)  
Admissions Committee, Stanford University Program in Cancer Biology, 1997-2001  
Dean's Executive Subcommittee for the Development of a Gene Therapy Program, Stanford University School of Medicine, 1995  
Admissions Committee, Stanford University School of Medicine, 1989-92  
Chair, Quality of Care Committee, Medical Service, Stanford Univ. Hospital, 1982-84  
Compromised Host Committee, Stanford University Hospital, 1982-86

**PEER REVIEW AND NIH ADVISORY ACTIVITIES:**

Grant Review Committee, Margaret E. Early Trust, 1995-present  
External Advisory Board, University of Texas , Houston, Center for Clinical and Translational Sciences, 2014-2016  
Marsha Rivkin Center for Ovarian Cancer Research, Pilot Study Award Program and Scientific Scholar Award Program Review Committee, 2010-14  
Member, Translational and Clinical Review Committee, Cancer Prevention and Research Institute of Texas (CPRIT), 2009-2012  
Chair, NIH Review Committee for Regional Translational Research Centers, 2005  
Chair, NIH Scientific Review Group, Experimental Therapeutics I Study Section, 2000-02  
Co-chair, Developmental Therapeutics Section, Progress Review Group in Gynecologic Cancers, National Cancer Institute (NCI), 2000-02  
Chair, Drug Resistance Session, Gastric Cancer State of the Science Workshop, NCI, 2001  
Member, NIH Scientific Review Group, Experimental Therapeutics I Study Section, 1997-2000  
Chair, NIH Scientific Review Committee, Phase I Trials of Anticancer Agents, 1997  
American Cancer Society, Scientific Advisory Committee on Drug Development, Hematology, and Pathology, 1991-1996 (Vice-chair, 1995; Chair, 1996)  
NIH Scientific Review Group, Gene Therapy of Cancer, 1992  
NIH Scientific Review Group, Outstanding Investigator Grant Program, 1984-1990  
NIH Representative, U. S. - Japan Agreement, Anticancer Drug Development, 1985, '90, '94  
American Cancer Society Institutional Research Grant Review Committee, 1984-86

Scientific Review Board, Margaret E. Early Medical Research Trust, 1983-present  
NIH Scientific Review Group, Clinical Development of Anticancer Agents, 1984, 1997  
NIH Scientific Review Group, Human Tumor Stem Cell Cloning Assay, 1982

**PROFESSIONAL SOCIETY COMMITTEES AND SYMPOSIA:**

Board of Directors, Cancer Molecular Therapeutics Research Association, 2010-present  
Member, Medical Oncology Subspecialty Board Examining Committee, American Board of Internal Medicine (ABIM), 2007-2013  
Member, Oncology Examining Committee, American College of Physicians MKSAP VII. Recertifying Course and Examination, 1983-85  
Program Committee, American Society of Hematology, 2000

**American Association for Cancer Research (AACR):**

QuadW Foundation-AACR Fellowship for Clinical/Translational Sarcoma Research Scientific Review Committee, 2013  
Gertrude B. Elion Cancer Research Award Scientific Review Committee, 2010  
Co-chair, Pharmacology, AACR Annual Meeting Program Committee, 2008-09  
Chair, Major Symposium on "Resistance to Targeted Therapies," AACR Annual Meeting, 2009  
Chair, AACR Forum, "Antisense: the Clinical Perspective," 2003 AACR Annual Meeting  
Co-chair, AACR Minisymposium, "Mechanisms and Modulation of Drug Resistance," 2003  
Co-chair, AACR Minisymposium, "Transporters and Drug Resistance," 2002  
Chair, Education Committee, AACR, 1999-2000  
Program Committee, AACR, 1995, 2001, 2002

**American Society of Clinical Oncology (ASCO):**

ASCO Translational Research Professorship Review Committee, 2007  
Chair, Best of ASCO Committee, American Society of Clinical Oncology (ASCO), 2006-07  
Chair, Scientific Program Committee, ASCO, 2005-6  
Member, ASCO Multidisciplinary Cancer Management Course Working Group, 2003-06  
International Affairs Committee, ASCO, 2003-06  
Awards Committee, ASCO, 1993-97 (Chair 1995-6)  
Co-chair, ASCO Integrated Symposium, "New Agents and New Targets," 2002  
Communications Committee, ASCO, 2000-03  
Program Committee, ASCO annual meeting, 1983, 1984, 1986, 1993, 2000, 2001 (Chair, Subcommittee on Clinical Pharmacology, 1993, 2001)

**EDITORIAL BOARDS:**

Associate Editor, *Journal of Experimental Therapeutics and Oncology*, 1995-2017  
Associate Editor, *Advances in Oncology*, 1992-2001  
Associate Editor, *American Journal of Medicine*, 1998-99  
Editorial Board, *Investigational New Drugs*, 2004-2017  
Editorial Board, *Molecular Cancer Therapeutics*, 2001-05  
Editorial Board, *The Oncologist*, 1995-2000  
Editorial Board, *Cancer Therapeutics*, 1997-99

**COOPERATIVE CLINICAL TRIALS GROUP PARTICIPATION:**

Chair, Pharmacology Committee, Eastern Cooperative Oncology Group (ECOG), 1992-2003  
Leukemia Committee, ECOG, 1991-2003

Laboratory Science Committee, ECOG, 1990-2003  
New Agents and Pilot Studies Committee (ECOG), 1990-92  
Chair, Chemotherapy and Drug Development Committee, Northern California Oncology Group (NCOG), 1987-1990  
Chair, Gynecologic Cancer Committee, NCOG, 1985-86  
Chair, Lung Cancer Committee, NCOG, 1983-85

**NATIONAL AND INTERNATIONAL CONTINUING EDUCATION ACTIVITIES:**

Advisor for a National Cancer Plan, Croatian Ministry of Health, 2017 – present  
Founder and Chair, Central European Oncology Congress and Best of ASCO Meeting Croatia, Opatija, Croatia, 2011-2019  
Founder and Chair, "Multidisciplinary Management of Cancers: a Case-Based Approach," sponsored by Stanford University School of Medicine, 2007-09, 2011-14  
Advisor on Cancer Policy, Ministry of Health and Ministry of Science, Education and Sport, Republic of Croatia, 2007-09  
Co-chair, Molecular Therapeutics of Cancer Conference (formerly the Gordon Conference on Cancer Therapeutics), Stanford University, 2009  
Founder and Chair, Northern California Tumor Board at Silverado, 2001-06  
Founder and Chair, Central European Oncology Congress, "Advances in Cancer Detection and Treatment," Opatija, Croatia, 1998, 2000, 2002, 2004, 2007, 2009  
Founder and Chair, First and Second UCSF Stanford Tumor Boards at Silverado, "A Multidisciplinary Approach to Cancer Treatment," Napa, CA, 1999 and 2000  
Chair, Symposium on "Current Treatment and Future Directions in the Management of Lung Cancer and Non-Hodgkin's Lymphoma," San Francisco, CA, 1997  
Co-chair, International Conference on Bleomycin Chemotherapy, San Francisco, CA, 1984

**STANFORD UNIVERSITY TEACHING:**

Stanford Undergraduate Honors Thesis Advisor

Course Lecturer:

Medical Student HHD221: "Anticancer Drugs 1" and "Anticancer Drugs 2"  
Med 199-217, "Undergraduate Research  
Pharmacology 201, 202  
Cancer Biology 243, "The Molecular and Cellular Biology of Cancer"  
Oncology Fellows and Radiotherapy Residents lecture series  
Human Biology 154, "Biosocial Aspects of Cancer," for undergraduates  
Human Biology 111/Biology 112, "Human Physiology" for undergraduates  
Cultural Anthropology 174: "Cultures of Disease: Cancer"

**ADVISORY BOARDS AND DATA SAFETY MONITORING COMMITTEES:**

Data Monitoring Committee, Protocol B7461006, Pfizer, Inc., 2017-present  
Chair, Data Monitoring Committee, Immune Design Corporation, 2014 - present  
Oncology Advisory Board, Threshold Pharmaceuticals, 2012 - 2016  
Clinical Advisory Board, NuMedii, In., 2013 – 14  
Oncology Advisory Board, Tetralogic Pharmaceuticals, 2012 - 13  
Data Monitoring Committee, Protocol A8081014, Pfizer, Inc., 2011-14  
Data Monitoring Committee, Protocol A6181087, Pfizer, Inc., 2007-10  
Data and Safety Monitoring Committee, California Cancer Consortium, 2007-12  
Scientific Advisor, Rudjer Boskovic Institute, Zagreb, Croatia, 2009-2012



Colorectal Cancer Advisory Board (Chair), Astrazeneca Corporation, 2006  
Scientific Advisory Board (Chair), Kanisa Pharmaceuticals, 2004-2009  
Oncology Advisory Board, RadioRx, Inc., 2012-2013  
Oncology Advisory Board, Johnson and Johnson, 2003-2012  
Clinical Advisory Board, Sunesis Pharmaceuticals, 2003-2007  
Oncology Advisory Board, Exelixis, Inc., 2002-06  
Oncology Advisory Board, Eli Lilly, Inc., 2002-03  
Oncology Advisory Board, Celera, Inc., 2001-03  
Oncology Advisory Board (Chair), Axys Pharmaceuticals, Inc., 1999-2001  
Scientific Advisory Board (Chair) Ontogen Corporation, 1998-2002  
Scientific Advisory Board, Rigel Pharmaceuticals, Inc., 1997-99  
Scientific Advisory Board, Pharmacyclics, Inc., 1996-2001 and 2009-2012  
Oncology Advisory Board, Isis Pharmaceuticals, Inc., 1996-2001  
Oncology Advisory Board, Glaxo-Wellcome Corporation, 1995-99  
Scientific Advisor, Pfeiffer Medical Research Foundation, 1995-2002  
Oncology Advisory Board, Novartis (Sandoz) Pharmaceuticals, 1992-99  
Oncology Advisory Board, Bristol-Myers Squibb Company, 1982-2004

**RESEARCH INTERESTS:**

The clinical and pre-clinical pharmacology of antineoplastic drugs:

Mechanisms of anti-cancer drug action and resistance

Multidrug resistance genes

Tubulin targeted agents

Epithelial to mesenchymal transition

Anticancer drug discovery and development

The CCL2/CCR2 pathway as an anticancer target

Inhibitors of IAPs as sensitizers for cancer therapies

CD47 as a therapeutic target in ovarian cancers

Genomics to define prognostic factors and determinants of therapeutic response:

Current and recent projects include studies of unknown primary cancers, colorectal carcinomas, ovarian and breast cancers, glioblastomas, and acute myeloid leukemias

Current Phase I trials of new anticancer agents and combinations:

Phase I first-in-human trial of the anti-CD47 antibody Hu5F9-G4 (sponsored by Stanford University and Forty Seven, Inc.)

Phase I/II study of a combination of antibodies against CD27 (varlilumab) and PD-1 (nivolumab) (sponsored by Celldex)

**ADDRESSES:** Oncology Division, CCSR North 1105  
Stanford University Medical Center  
Stanford, CA 94305-5151  
Tel. (650) 725-6427,  
FAX: (650) 736-1454  
E-mail: brandy@stanford.edu

Web site: [http://med.stanford.edu/labs/branimir\\_sikic/](http://med.stanford.edu/labs/branimir_sikic/)

**BIBLIOGRAPHY:****Peer Reviewed Articles:**

1. Sikic BI, Walker RD and Peterson DR: An evaluation of a program for the treatment of alcoholism in Croatia. *Alcoholism* 1: 109-20, 1972. Also in: *Int J Soc Psych* 171-82, 1972. PMID: 4670080.
2. Renault PF, Schuster CR, Freedman DX, Sikic BI, de Mello D and Halaris A: Repeat administration of marihuana smoke to humans. *Arch Gen Psych* 31: 95-102, 1974. PMID: 4835990.
3. Sikic BI and Baumel IP: The interaction of flurazepam with diphenylhydantoin in rats. *Drug Metab Dispos* 4: 584-586, 1976. PMID: 11981.
4. Sikic BI, Mimnaugh EG, Litterst CL and Gram TE: The effects of ascorbic acid deficiency and repletion on pulmonary, renal, and hepatic drug metabolism in the guinea pig. *Arch Biochem Biophys* 179: 663-671, 1977. PMID: 403863.
5. Sikic BI, Mimnaugh EG and Gram TE: Effects of dietary ascorbic acid supplementation on hepatic drug-metabolizing enzymes in the guinea pig. *Biochem Pharmacol* 26:2037-41, 1977. PMID: 411495.
6. Sikic BI, Young DM, Mimnaugh EG and Gram TE: Quantification of bleomycin pulmonary toxicity in mice by changes in lung hydroxyproline content and morphometric histopathology. *Cancer Res* 38: 787-792, 1978. PMID: 75060.
7. Mimnaugh EG, Waring RW, Sikic BI, Magin RL, Drew R, Litterst CL, Gram TE, and Guarino AM: The effect of whole body hyperthermia on the disposition and metabolism of adriamycin in rabbits. *Cancer Res* 38: 1420-1425, 1978. PMID: 639069.
8. Sikic BI, Collins JM, Mimnaugh EG and Gram TE: Improved therapeutic index of bleomycin when administered by continuous infusion in mice. *Cancer Treat Rep* 62: 2011-2017, 1978. PMID: 87269.
9. Litterst CL, Sikic BI, Mimnaugh EG, Guarino AM and Gram TE: In vitro drug metabolism in male and female athymic, nude mice. *Life Sci* 22: 1723-1730, 1978. PMID: 672423.
10. Mimnaugh EG, Siddik ZH, Drew R, Sikic BI and Gram TE: The effects of alpha-tocopherol on the toxicity, disposition, and metabolism of adriamycin in mice. *Toxicol Appl Pharmacol* 49: 119-126, 1979. PMID: 473197.
11. Magin RL, Sikic BI and Cysyk RL: Enhancement of bleomycin activity against Lewis lung tumors in mice by local hyperthermia. *Cancer Res* 39: 3792-3795, 1979. PMID: 89905.
12. Siddik ZH, Sikic BI, Drew R, Mimnaugh EG, Litterst CL and Gram TE: Lack of correlation between cortisol-induced precocious maturation of the fetal rabbit lung and drug metabolism. *Biochem Pharmacol* 28: 683-685, 1979. PMID: 444254.
13. Drew R, Sikic BI, Mimnaugh EG, Litterst CL and Gram TE: The distribution of 14C-imipramine in mice bearing Lewis lung carcinoma. *Life Sci* 25: 1813-1820, 1979. PMID: 529988.
14. Sikic BI, Siddik ZH and Gram TE: Relative pulmonary toxicity and antitumor effects of two new bleomycin analogues, pepleomycin and tallysomycin A. *Cancer Treat Rep* 64: 659-667, 1980. PMID: 6159079.
15. Siddik ZH, Drew R, Litterst CL, Mimnaugh EG, Sikic BI and Gram TE: Hepatic cytochrome P-450-dependent metabolism and enzymatic conjugation of foreign compounds in vitamin A deficient rats. *Pharmacology* 21: 383-390, 1980. PMID: 7220590.
16. Rahman A, Kessler A, More N, Sikic B, Rowden G, Woolley P and Schein PS: Liposomal protection of adriamycin-induced cardiotoxicity in mice. *Cancer Res* 40: 1532-1537, 1980. PMID: 7370991.

17. Gullo JJ, Litterst CL, Maguire PJ, Sikic BI, Hoth DF and Woolley PV: Pharmacokinetics and protein binding of cis-dichlorodiammine platinum (II) administered as a one hour or as a twenty hour infusion. *Cancer Chemother Pharmacol* 5: 21-26, 1980. PMID: 6161715.
18. Ahlgren JD, Smith FP, Kerwin DM, Sikic BI, Weiner JH and Schein PS: Pulmonary disease as a complication of chlorozotocin chemotherapy. *Cancer Treat Rep* 65: 223-229, 1981. PMID: 6453644.
19. MacKintosh FR, Evans TL and Sikic BI: Methodologic problems in clonogenic assays of spontaneous human tumors. *Cancer Chemother Pharmacol* 6: 205-210, 1981. PMID: 7032738.
20. Litterst CL, Torres IJ, Arnold S, McGunagle D, Furner R, Sikic BI and Guarino AM: Absorption of antineoplastic drugs following large-volume intraperitoneal administration to rats. *Cancer Treat Rep* 66: 147-155, 1982. PMID: 7053249.
21. Chak LY, Daniels JR, Sikic BI, Torti FM, Lockbaum P and Carter SK: Patterns of failure in small cell carcinoma of the lung. *Cancer* 50: 1857-1863, 1982. PMID: 6288227.
22. Harker WG, MacKintosh FR, and Sikic BI: Development and characterization of a human sarcoma cell line, MES-SA, sensitive to multiple drugs. *Cancer Res* 43: 4943-4950, 1983. PMID: 6883344.
23. Chak LY, Paryani SB, Sikic BI, Lockbaum P, Torti FM and Carter SK: Diagnostic accuracies of clinical studies in patients with small cell carcinoma of the lung. *J Clin Oncol* 1: 290-294, 1983. PMID: 6321683.
24. Carlson RW, Sikic BI, Turbow MM and Ballon SC: Combination cisplatin, vinblastine, and bleomycin chemotherapy (PVB) for malignant germ-cell tumors of the ovary. *J Clin Oncol* 1: 645-651, 1983. PMID: 6199468.
25. Chak LY, Sikic BI, Tucker MA, Horns RC, and Cox RS: Increased incidence of acute nonlymphocytic leukemia following therapy in patients with small cell carcinoma of the lung. *J Clin Oncol* 2: 385-390, 1984. PMID: 6327924.
26. Ballon SC, Portnuff JC, Sikic BI, Turbow MM, Teng NNH and Soriero OM: Second-look laparotomy in epithelial ovarian carcinoma: precise definition, sensitivity, and specificity of the operative procedure. *Gynecol Oncol* 17: 154-160, 1984. PMID: 6706223.
27. Daniels JR, Chak LY, Sikic BI, Lockbaum P, Kohler M, Carter SK, Reynolds R, Bohnen R, Gandara D, and Yu J: Chemotherapy of small-cell carcinoma of lung: a randomized comparison of alternating and sequential combination chemotherapy programs. *J Clin Onc* 2: 1192-1199, 1984. PMID: 6092554.
28. Turbow MM, Ballon S, Sikic BI, and Koretz M: Cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced endometrial carcinoma. *Cancer Treat Rep* 69: 465-467, 1985. PMID: 4039978.
29. Picozzi VJ, Sikic BI, Carlson RW, Koretz M, and Ballon SB: Bleomycin, mitomycin, and cisplatin therapy for advanced squamous carcinoma of the uterine cervix: a phase II study of the Northern California Oncology Group. *Cancer Treat Rep* 69: 903-905, 1985. PMID: 2410123.
30. Weber S, Zuckerman JE, Bostwick DG, Bensch KG, Sikic, BI and Raffin TA: Gastrin releasing peptide is a selective mitogen for small cell lung carcinoma in vitro. *J. Clin. Investig.* 75: 306-309, 1985. PMID: 2981251.
31. Sikic BI, Ehsan MN, Harker WG, Friend NF, Brown BW, Newman RA, Fagan MA, and Acton EM: Dissociation of antitumor potency from anthracycline cardiotoxicity in a doxorubicin analog. *Science, (Wash., D. C.)* 228: 1544-1546, 1985. PMID: 4012308.
32. Levin VA, Byrd D, Sikic BI, Etiz BB, Campbell J, Borcich JK, and Davis RL: Central nervous system toxicity and cerebrospinal fluid pharmacokinetics of intraventricularly administered bleomycin in beagles. *Cancer Res* 45: 3810-3815, 1985. PMID: 2410102.

33. Harker WG, and Sikic BI: Multidrug (Pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line, MES-SA. *Cancer Res* 45: 4091-4096, 1985. PMID: 4028002.
34. Chak LY, Zatz LM, Wasserstein P, Cox RS, Kushlan PD, Porzig KJ, and Sikic BI: Neurologic dysfunction in patients treated for small cell carcinoma of the lung: a clinical and radiological study. *Int J Radiation Oncol Biol Physics* 12: 385-389, 1986. PMID: 3007408.
35. Zuckerman JE, Raffin TA, Brown JM, Newman RA, Etiz BB, and Sikic BI: In vitro selection and characterization of a bleomycin-resistant subline of B16 melanoma. *Cancer Res* 46: 1748-1753, 1986. PMID: 2418953.
36. Harker WG, Bauer D, Etiz BB, Newman RA, and Sikic BI: Verapamil-mediated sensitization of doxorubicin-selected pleiotropic resistance in human sarcoma cells: selectivity for drugs which produce DNA scission. *Cancer Res* 46: 2369-2373, 1986. PMID: 3754487.
37. Schray MF, Martinez A, Howes AE, Ballon SC, Podratz KC, Sikic BI, and Malkasian GD: Advanced epithelial ovarian cancer: toxicity of whole abdominal irradiation after operation, combination chemotherapy, and re-operation. *Gynecol Oncol* 24: 68-80, 1986. PMID: 3699578.
38. Langlotz CP, Fagan LM, Tu SW, Sikic BI, and Shortliffe EH: Combining artificial intelligence and decision analysis for automated therapy planning assistance. In: *MEDINFO 86*, Salamon R, Blum B, and Jorgensen M (Eds.) Elsevier Science Publishers, North Holland, 1986, pp. 794-798.
39. Sikic BI, Scudder SA, Ballon SC, Soriero OM, Christman JE, Suey L, Ehsan MN, Brandt AE, and Evans TL: High dose megestrol acetate therapy of ovarian carcinoma: A phase II study of the Northern California Oncology Group. *Sem Oncol* 13: (Suppl. 4) 26-32, 1986. PMID: 3099393.
40. DeGregorio MW, Lum BL, Holleran WM, Wilbur BJ, and Sikic BI: Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase I study of the Northern California Cancer Program. *Cancer Chemother Pharmacol* 18: 235-238, 1986. PMID: 3542268.
41. Yamauchi T, Raffin TR, Yang P, and Sikic BI: Differential protective effects of varying degrees of hypoxia on the cytotoxicities of etoposide and bleomycin. *Cancer Chemother Pharmacol* 19: 282-286, 1987. PMID: 2439223.
42. Langlotz CP, Fagan LM, Tu SW, Sikic BI, and Shortliffe EH: A therapy planning architecture that combines decision theory and artificial intelligence techniques. *Computers and Biomedical Res.* 20: 279-303, 1987. PMID: 3301187.
43. Berinstein N, Matthey KK, Papahadjopoulos D, Levy R, and Sikic BI: Antibody-directed targeting of liposomes to human cell lines: role of binding and internalization on growth inhibition. *Cancer Res* 47: 5954-5959, 1987. PMID: 3664498.
44. Coleman CN, Carlson RW, Halsey J, Kohler M, Gribble M, Sikic BI, and Jacobs C: Enhancement of the clinical activity of melphalan by the hypoxic cell sensitizer misonidazole. *Cancer Res* 48: 3528-3532, 1988. PMID: 2836059.
45. Uemura M, Winant RC, Sikic BI, and Brandt AE: Characterization and immunoassay of human tumor-associated galactosyltransferase isoenzyme II. *Cancer Res* 48: 5325-34, 1988. PMID: 3136919.
46. Beckman RA, McFall PJ, Sikic BI, and Smith SD: Doxorubicin and the alkylating anthracycline MRA-CN: comparative in vitro potency against leukemic and bone marrow cells. *J Natl Cancer Inst* 80: 361-365, 1988. PMID: 3357201.
47. Schray MF, Martinez A, Howes AE, Podratz KC, Ballon SC, Malkasian GD, and Sikic BI: Advanced epithelial ovarian cancer: salvage whole abdominal irradiation for patients with recurrent or persistent disease after combination chemotherapy. *J Clin Oncol* 6: 1433-9, 1988. PMID: 3418375.

48. Scudder SA, Brown JM, and Sikic BI: DNA cross-linking and cytotoxicity of the alkylating anthracycline cyanomorpholino-doxorubicin (MRA-CN) in multidrug resistant cells. *J Natl Cancer Inst* 80: 1294-1298, 1988. PMID: 3172256.
49. Lau DHM, Lewis AL, and Sikic BI: Association of DNA cross-linking with potentiation of the morpholino derivative of doxorubicin by human liver microsomes. *J Natl Cancer Inst* 81: 1034-1038, 1989. PMID: 2733045.
50. Parce JW, Owicki JC, Kercso KM, Sigal GB, Wada HG, Muir VC, Bousse LJ, Ross KL, Sikic BI, and McConnell HM: Detection of cell-affecting agents with a silicon biosensor. *Science (Wash., D. C.)* 246: 243-247, 1989. PMID: 2799384.
51. Gosland MP, Lum BL, and Sikic BI: Reversal by cefoperazone of resistance to etoposide, doxorubicin, and vinblastine in multidrug resistant human sarcoma cells. *Cancer Res* 49: 6901-6905, 1989. PMID: 2582432.
52. Lau DHM, Ross KL, and Sikic BI: Paradoxical increase in DNA cross-linking in a human ovarian carcinoma cell line resistant to cyanomorpholino doxorubicin, MRA-CN. *Cancer Res* 50: 4056-4060, 1990. PMID: 2162251.
53. John M, Flam M, Sikic B, Rotman M, Cooper J, Phillips T, Malec M, Hannigan J, and Phillips T: Preliminary results of concurrent radiotherapy and chemotherapy in advanced cervical carcinoma: a phase I-II prospective intergroup NCOG-RTOG study. *Gynecol Oncol* 37: 1-5, 1990. PMID: 2108909.
54. Christman JE, and Sikic BI: Delivery of a normal infant following cisplatin, vinblastine, and bleomycin (PVB) chemotherapy for malignant teratoma of the ovary during pregnancy. *Gynecol Oncol* 37: 292-295, 1990. PMID: 1693127.
55. Carlson RW, Dorfman RF, and Sikic BI: Successful treatment of metastatic thymic carcinoma with cisplatin, vinblastine, bleomycin, and etoposide chemotherapy. *Cancer* 66: 2092-2094, 1990. PMID: 1699650.
56. Aihara M, Sikic BI, Blume KG, and Chao NJ: Assessment of purging with multidrug-resistance (MDR) modulators and VP-16: results of long-term marrow culture. *Exp Hematol* 18: 940-944, 1990. PMID: 2387345.
57. Berry JM, Jacobs C, Sikic B, Halsey J, and Borch RF: Modification of cisplatin toxicity with diethyldithiocarbamate. *J Clin Oncol* 8: 1585-1590, 1990. PMID: 2167955.
58. Chao NJ, Aihara M, Blume KG, and Sikic BI: Modulation of etoposide (VP-16) cytotoxicity by verapamil or cyclosporine in multidrug-resistant human leukemic cell lines and normal bone marrow. *Exp Hematol* 18: 1193-1198, 1990. PMID: 2226679.
59. Aihara M, Aihara Y, Schmidt-Wolf G, Schmidt-Wolf I, Sikic BI, Blume KG, and Chao NJ: A combined approach for purging multidrug resistant leukemic cell lines in bone marrow using a monoclonal antibody and chemotherapy. *Blood* 77: 2079-2084, 1991. PMID: 1673356.
60. Carlson RW, Sikic BI, Gandara DR, Hendrickson CG, Wittlinger PS, Shields JA, Wong PP, White JE, Meakin CJ, McWhirter KM, Lamborn KR, and Phillips TL: Late consolidative radiotherapy in the treatment of limited-stage small cell lung cancer. *Cancer* 68: 948-958, 1991. PMID: 1655219.
61. Marie JP, Zittoun R, and Sikic BI: Multidrug resistance (*mdr1*) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. *Blood* 78: 586-592, 1991. PMID: 1859877.
62. Lau DHM, Lewis AD, Ehsan MN, and Sikic BI: Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin. *Cancer Res* 51: 5181-5187, 1991. PMID: 1717140.

63. Jacobs C, Kaubisch S, Halsey J, Lum BL, Gosland M, Coleman CN, and Sikic BI: The use of probenecid as a chemoprotector against cisplatin nephrotoxicity. *Cancer* 67: 1518-24, 1991. PMID: 1848154.
64. Marie JP, Brophy NB, Ehsan MN, Aihara Y, Mohamed NA, Cornbleet J, Chao NJ, and Sikic BI: Expression of multidrug resistance gene *mdr1* mRNA in a subset of normal bone marrow cells. *Br J Haematol* 81: 145-152, 1992. PMID: 1353683.
65. Lewis AD, Duran GE, Lau DHM, and Sikic BI: Sensitization of drug resistant human ovarian cancer cells to cyanomorpholino doxorubicin (MRA-CN) by modulation of glutathione metabolism. *Int J Radiation Oncol Biol Physics*, 22: 821-4, 1992. PMID: 1544857.
66. Lau DHM, Duran GE, and Sikic BI: Characterization of the covalent DNA binding of the morpholino and cyanomorpholino derivatives of doxorubicin. *J Natl Cancer Inst* 84: 1587-1592, 1992. PMID: 1404452.
67. Lewis AD, Lau DHM, Duran GE, Wolf CR, and Sikic BI: Role of cytochrome P-450 from the human CYP3A gene family in the potentiation of morpholino doxorubicin by human liver microsomes. *Cancer Res* 52: 4379-4384, 1992. PMID: 1643634.
68. Kühl J-S, Sikic BI, Blume KG, and Chao NJ: Use of etoposide in combination with cyclosporin for purging multidrug-resistant leukemic cells from bone marrow in a mouse model. *Exp Hematol* 20: 1048-1054, 1992. PMID: 1468539.
69. Yahanda AM, Adler KM, Fisher G, Brophy NA, Hardy R, Halsey J, Gosland MP, Lum BL, and Sikic BI: A phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. *J Clin Oncol* 10: 1624-1634, 1992. PMID: 1403040.
70. Lum BL, Kaubisch S, Yahanda AM, Adler KM, Jew L, Ehsan MN, Halsey J, Gosland MP, and Sikic BI: Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial of modulation of multidrug resistance. *J Clin Oncol* 10: 1635-1642, 1992. PMID: 1403041.
71. Kühl J-S, Durán GE, Chao NJ, and Sikic BI: Effects of the methoxymorpholino derivative of doxorubicin and its bioactivated form versus doxorubicin on human leukemia and lymphoma cell lines and normal bone marrow. *Cancer Chemother Pharmacol* 33: 10-16, 1993. PMID: 8269583.
72. Lum BL, Fisher GA, Brophy NA, Yahanda AM, Adler KM, Kaubisch S, Halsey J, and Sikic BI: Clinical trials of modulation of multidrug resistance: pharmacokinetic and pharmacodynamic considerations. *Cancer* 72: 3502-3514, 1993. PMID: 7902206.
73. Brophy NA, Marie J-P, Rojas VA, Warnke RA, McFall PJ, Smith SD, and Sikic BI: *Mdr1* gene expression in childhood acute lymphoblastic leukemias and lymphomas: a critical evaluation by four techniques. *Leukemia* 8: 327-335, 1994. PMID: 7905944.
74. Jaffr  zou J-P, Sikic BI, and Laurent G: Cyclosporin A and cyclosporin SDZ PSC 833 enhance anti-CD5 ricin A-chain immunotoxins in human leukemic T cells. *Blood* 83: 482-489, 1994. PMID: 7506953.
75. Bartlett NL, Lum BL, Fisher GA, Brophy NA, Ehsan MN, Halsey J, and Sikic BI: A phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. *J Clin Oncol* 12: 835-842, 1994. PMID: 8151326.
76. Jaffr  zou J-P, Chen G, Dur  n GE, K  hl J-S, and Sikic BI: Mutation rates and mechanisms of resistance to etoposide determined from fluctuation analysis. *J Natl Cancer Inst.* 86: 1152-1158, 1994. PMID: 8028036.
77. Lau DHM, Duran GE, Lewis AD, and Sikic BI: Metabolic conversion of methoxy-morpholinyl doxorubicin: from a DNA strand-breaker to a DNA cross-linker. *Br J Cancer* 70: 79-84, 1994. PMID: 8018545.

78. Chen G, Jaffrezou J-P, Fleming WH, Duran GE, and Sikic BI: Prevalence of multidrug resistance related to activation of the *mdr1* gene in human sarcoma mutants derived by single-step doxorubicin selection. *Cancer Res* 54: 4980-4987, 1994. PMID: 7915196.
79. Dong Y-j, Chen G, Duran GE, Kouyama K, Chao AC, Sikic BI, Gollapudi SV, Gupta S, and Gardner P: Volume-activated chloride current is not related to P-glycoprotein overexpression. *Cancer Res* 54: 5029-5032, 1994. PMID: 7923110.
80. Lau DHM, Duran GE, and Sikic BI: Analysis of intracellular retention of morpholinyl anthracyclines in multidrug resistant cells by interactive laser cytometry. *Int J Oncology* 5: 1273-1277, 1994. PMID: 21559709.
81. Muller C, Goubin F, Ferrandis E, Cornil-Schwartz I, Bailly JD, Bordier C, Benard J, Sikic BI, and Laurent G: Evidence for transcriptional control of human *mdr1* gene expression by verapamil in multidrug-resistant leukemic cells. *Mol Pharmacol* 47: 51-56, 1995. PMID: 838133.
82. Cufer T, Vrhovec I, Skrk J, Pfeifer M, Pajk B, Zakotnik B, Filipic B, Rode B, and Sikic BI: Cyclosporine A increases serum cortisol levels in rabbits. *Anti-Cancer Drugs* 6: 615-618, 1995. PMID: 7579569.
83. Marie J-P, Simonin G, Legrand O, Delmer A, Faussat A-M, Lewis AD, Sikic BI, and Zittoun R: Glutathione-S transferases  $\pi$ ,  $\alpha$ , and  $\mu$  and *mdr1* mRNA expression in normal lymphocytes and chronic lymphocytic leukaemia. *Leukemia* 9: 1742-1747, 1995. PMID: 7564519.
84. Jaffrezou J-P, Chen G, Duran G, Muller C, Bordier C, Laurent G, Sikic BI, and Levade T: Inhibition of lysosomal acid sphingomyelinase by agents which reverse multidrug resistance. *Biochim Biophys Acta* 1266: 1-8, 1995. PMID: 7718613.
85. Beketic-Oreskovic L, Duran GE, Chen G, Dumontet C, and Sikic BI: Decreased mutation rate for doxorubicin resistance and suppression of *mdr1* gene activation by PSC 833. *J Natl Cancer Inst* 87: 1593-1602, 1995. PMID: 7563202.
86. Jaffrezou J-P, Dumontet C, Derry WB, Duran G, Chen G, Tsuchiya E, Wilson L, Jordan MA, and Sikic BI: Novel mechanism of resistance to paclitaxel (Taxol) in human K562 leukemia cells by combined selection with PSC 833. *Oncology Res* 7: 517-527, 1995. PMID: 8866664.
87. McCauley DL, Lum BL, and Sikic BI: Effect of different mathematical methods on etoposide area under the curve values and pharmacodynamic response predictions. *Cancer Chemother Pharmacol* 37: 286-288, 1996. PMID: 8529291.
88. Luckie DB, Krouse ME, Law TC, Sikic BI, and Wine JJ: Doxorubicin selection for MDR1/P-glycoprotein reduces swelling-activated  $K^+$  and  $Cl^-$  currents in MES-SA cells. *Am J Physiol* 270 (Cell Physiol. 39): C1029-C1036, 1996. PMID: 928730.
89. Duran GE, Lau DHM, Lewis AD, Kühl J-S, Bämmler TK, and Sikic BI: Differential single-versus double-strand DNA breakage produced by doxorubicin and its morpholinyl analogues. *Cancer Chemother Pharmacol* 38: 210-216, 1996. PMID: 8646794.
90. Dumontet C, Duran GE, Steger KA, Beketic-Oreskovic L, and Sikic BI: Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). *Cancer Res* 56: 1091-1097, 1996. PMID: 640766.
91. Beck WT, Grogan TM, Willman CL, Cordon-Cardo C, Parham DM, Kuttesch JF, Andreeff M, Bates SE, Berard CW, Boyett JM, Brophy NA, Broxterman HJ, Chan HSL, Dalton WS, Dietel M, Fojo AJ, Gascoyne RD, Head D, Houghton PJ, Srivastava DK, Leith CP, Lehnert M, Paietta E, Pavelic ZP, Rimzsa L, Roninson IB, Sikic BI, Twentymen PR, Warnke R, and Weinstein R: Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. *Cancer Res* 56: 3010-3020, 1996. PMID: 8674056.
92. Dumontet C, Duran GE, Steger KA, Murphy G, Sussman H, and Sikic BI: Differential expression of tubulin isotypes during the cell cycle. *Cell Motility Cytoskel*, 35: 49-58, 1996. PMID: 8874965.

93. Kühl J-S, Krajewski S, Duran GE, Reed JC, and Sikic BI: A spontaneously resistant variant of murine P388 leukemia with broad cross-resistance to cytotoxins and overexpression of the long form of the Bcl-X protein. *Br J Cancer* 75: 268-274, 1996. PMID: 9010037.
94. Chen G, Durán GE, Steger KA, Lacayo NJ, Jaffrézou JP, Dumontet C, and Sikic BI: Multidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype, and resistance to cyclosporins. *J Biol Chem* 272: 5974-5982, 1997. PMID: 9038218.
95. Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, and Chen G: Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. *Cancer Chemother Pharmacol* 40 (Suppl): S13-S19, 1997. PMID: 9272128.
96. Advani R, Warnke R, Sikic BI, and Horning S: Treatment of angioimmunoblastic T-cell lymphoma with cyclosporine. *Ann Oncol* 8: 601-603, 1997. PMID: 9261530.
97. Lum BL, Lane KJ, Synold TW, Goram A, Charnick SB, and Sikic BI: Validation of a limited sampling model for etoposide area under the curve determinations. *Pharmacotherapy* 17: 887-890, 1997. PMID: 9324178.
98. Cufer T, Vrhovec I, Pfeifer M, Skrk J, Borstnar S, and Sikic BI: Effect of the multidrug resistance modulator valsopodar on serum cortisol levels in rabbits. *Cancer Chemother. Pharmacol.* 41: 517-521, 1998. PMID: 9554598.
99. Washington CB, Duran GE, Man MC, Sikic BI, and Blaschke TF: Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells. *J Acquir Immune Defic Syndr Hum Retrovirol* 19: 203-209, 1998. PMID: 9803961.
100. Tallman MS, Lee S, Sikic BI, Paietta E, Bennett JM, Rowe JM, and Wiernik PH: Mitoxantrone, etoposide, and cytarabine plus cyclosporine in patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Group pilot study. *Cancer* 85: 358-367, 1999. PMID: 10023703.
101. Sikic BI: Author update. (Lum BL, Kaubisch S, Yahanda AM, Adler KM, Jew L, Ehsan MN, Halsey J, Gosland MP, and Sikic BI: Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial of modulation of multidrug resistance. *J. Clin. Oncol.* 10: 1635-1642, 1992). *Classic Papers and Current Comments: Highlights of Cancer Pharmacology Research*, 4: 140-147, 1999. PMID: 1403041.
102. Advani R, Saba HI, Tallman MS, Rowe JM, Wiernik PH, Ramek J, Dugan K, Lum B, Villena J, Davis E, Paietta E, Litchman M, Sikic BI, and Greenberg PL: Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (valsopodar). *Blood* 93: 787-795, 1999. PMID: 9920827.
103. Yuen AR, Halsey J, Fisher GA, Geary RS, Macias D, Holmlund JT, Dorr A, and Sikic BI: Phase I study of antisense oligonucleotide to protein kinase C- $\alpha$  (Isis 3521/CGP64128A) in patients with cancer. *Clin Cancer Res* 5: 3357-3363, 1999. PMID: 10589745.
104. Lum BL, Kaubisch S, Fisher GA, Brown BW, and Sikic BI: Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance. *Cancer Chemother Pharmacol* 45: 305-311, 2000. PMID: 10755319.
105. Dahl GV, Lacayo NJ, Brophy N, Dunussi-Joannopoulos K, Weinstein HJ, Chang M, Sikic BI, and Arceci RJ: Mitoxantrone, etoposide, and cyclosporine (MEC) therapy in pediatric patients with recurrent or refractory acute myeloid leukemia. *J Clin Oncol* 18: 1867-1875, 2000. PMID: 0784627.
106. Chen GK, Lacayo NJ, Duran GE, Cohen D, and Sikic BI: Loss of cyclosporin and azidopine binding are associated with altered ATPase activity by a mutant P-glycoprotein with deleted Phe<sup>335</sup>. *Mol Pharmacol*, 57: 769-777, 2000. PMID: 10727524.
107. Yuen AR and Sikic BI: Clinical studies of antisense therapy in cancer. *Front. Biosci.* 5: D588-93, 2000. PMID: 10833467. <http://www.bioscience.org/2000/v5/d/yuen/fulltext.htm>



108. Chen GK, Duran GE, Mangili A, Beketic-Oreskovic L, and Sikic BI: MDR1 activation is the predominant resistance mechanism selected by vinblastine in MES-SA cells. *Br J Cancer* 83: 892-898, 2000. PMID: 10970691.
109. Cufer T, Pfeifer M, Vrhovec I, Frangez R, Kosec M, Mrhar A, Grabnar I, Golouh R, Vogric S, and Sikic BI: Decreased cortisol secretion by adrenal glands perfused with the P-glycoprotein inhibitor valspodar and mitotane or doxorubicin. *Anticancer Drugs* 11: 303-309, 2000. PMID: 10898547.
110. Leo C, Jang Y, Chan E, Padilla D, Huang BC, Lin T, Gururaja T, Hitoshi Y, Lorens JB, Anderson DC, Sikic B, Luo Y, Payan DG, Xu X, and Nolan GP: Dominant effector genetics in mammalian cells. *Nat Genet* 27: 23-29, 2001. PMID: 11137994.
111. Advani R, Fisher GA, Lum BL, Hausdorff J, Halsey J, Litchman M, and Sikic BI: A Phase I trial of doxorubicin, paclitaxel and valspodar (PSC 833), a modulator of multidrug resistance. *Clin Cancer Res* 7: 1221-1229, 2001. PMID: 11350887.
112. Miller RA, Woodburn KW, Fan Q, Lee I, Miles D, Duran G, Sikic BI, and Magda D: Motexafin gadolinium: a redox active drug that enhances the efficacy of bleomycin and doxorubicin. *Clin Cancer Res* 7: 3215-3221, 2001. PMID: 11595717.
113. Sale S, Sung R, Shen P, Yu K, Wang Y, Duran GE, Kim J-H, Fojo T, Oefner P, and Sikic BI: Conservation of the class I beta tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel resistant ovarian cancers. *Mol Cancer Ther* 1: 215-225, 2002. PMID: 12467216.
114. Chen GK, Lacayo NJ, Duran GE, Wang Y, Bangs CD, Rea S, Kovacs M, Cherry AM, Brown JM, and Sikic BI: Preferential expression of a mutant allele of the amplified ABCB1 gene in drug-resistant variants of a human sarcoma. *Genes Chromosomes Cancer* 34: 372-383, 2002. PMID: 12112526.
115. Lacayo NJ, Lum BL, Becton BL, Weinstein H, Ravindranath Y, Chang MN, Bomgaars L, Lauer SJ, Sikic BI and Dahl GV: Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia. *Leukemia* 16: 920-927, 2002. PMID: 11986955.
116. Sale S, Oefner PJ, and Sikic BI: Re: Genetic analysis of the b tubulin gene, TUBB, in non-small-cell lung cancer. *J Natl Cancer Inst* 94: 776-777, 2002. PMID: 12011233.
117. Chin DL, Lum BL, and Sikic BI: Rapid determination of PEGylated liposomal doxorubicin and its major metabolite in human plasma by UV/visible HPLC. *J Chromatogr B* 779: 259-269, 2002. PMID: 12361740.
118. Schaner ME, Ross DT, Ciaravino G, Sorlie T, Troyanskaya O, Diehn M, Wang YC, Duran GE, Sikic TL, Caldeira S, Skomedal H, Tu IP, Hernandez-Boussard T, Johnson SW, O'Dwyer PJ, Fero MJ, Kristensen GB, Borresen-Dale AL, Hastie T, Tibshirani R, Van De Rijn M, Teng NN, Longacre TA, Botstein D, Brown PO, and Sikic BI: Gene expression patterns in ovarian carcinomas. *Mol Biol Cell*, 14: 4376-4386, 2003. PMID: 12960427.
119. Advani R, Fisher GA, Lum BL, Jambalos C, Cho CD, Cohen M, Gollerkeri A, and Sikic BI: Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies. *Clin Cancer Res*, 9: 5187-5194, 2003. PMID: 14613998.
120. Lacayo NJ, Duran GE, and Sikic BI: Modulation of resistance to idarubicin by the cyclosporin PSC 833 (valspodar) in multidrug resistant (MDR) cells. *J Exp Ther Oncol*, 3: 127-135, 2003. PMID: 14641819.
121. Hartman, AR, Grekowicz A, Lum BL, Carlson RW, Shurman C, Sikic BI, Shapiro R, and Stockdale FE: Phase I trial of uracil-ftorafur, leucovorin, and etoposide: an active all-oral regimen for metastatic breast cancer. *Breast Cancer Res Treat*, 82: 61-69, 2003. PMID: 14672404.

122. Advani R, Peethambaram P, Lum BL, Fisher GA, Hartmann L, Long HJ, Halsey J, Holmlund JT, Dorr A, and Sikic BI: A Phase II trial of aprinocarsen (Isis 3521, LY900003), an antisense oligonucleotide inhibitor of protein kinase C alpha administered as a 21-day infusion to patients with advanced ovarian cancer. *Cancer* 100: 321-326, 2004. PMID: 14716767.
123. Chen GK, Sale S, Tan T, Ermoian RP, and Sikic BI: CCAAT/enhancer-binding protein beta (nuclear factor for interleukin 6) transactivates the human *MDR1* gene by interaction with an inverted CCAAT box in human cancer cells. *Mol Pharmacol*, 65: 906-16, 2004. PMID: 15044620.
124. Greenberg PL, Lee SJ, Advani R, Tallman MS, Sikic BI, Letendre L, Dugan K, Lum BL, Chin DL, Dewald G, Paietta E, Bennett JM, and Rowe JM: Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a Phase III Trial (E2995). *J Clin Oncol*, 22: 1078-86, 2004. PMID: 15020609.
125. Lacayo NJ, Meshinchi S, Kinnunen P, Yu R, Wang Y, Stuber CM, Douglas L, Wahab R, Becton DL, Weinstein H, Chang MN, Willman CL, Radich JP, Tibshirani R, Ravindranath Y, Sikic BI, and Dahl GV. Gene expression profiles at diagnosis in *de novo* childhood AML patients identify FLT3 mutations with good clinical outcomes. *Blood*, 104: 2646-54, 2004. PMID: 15251987.
126. Tu IP, Schaner M, Diehn M, Sikic BI, Brown PO, Botstein D, and Fero MJ. A method for detecting and correcting feature misidentification on expression microarrays. *BMS Genomics*, 5: 64, 2004. PMCID: PMC521069. PMID: 15357875.
127. Dumontet C, Jaffrezou JP, Tsuchiya E, Duran GE, Chen G, Derry WB, Wilson L, Jordan MA, and Sikic BI. Resistance to microtubule-targeted cytotoxins in a K562 leukemia cell variant associated with altered tubulin expression and polymerization. *Bull Cancer*, 91: E81-112, 2004. PMID: 15568225.
128. Bredel M, Bredel C, Juric D, Kim Y, Vogel H, Garsh GR, Recht LD, Pollack JR, and Sikic BI. Amplification of whole tumor genomes from limited sources of fresh-frozen and paraffin-embedded DNA. *J Mol Diagn*, 7: 171-82, 2005. PMCID: PMC1867518. PMID: 15858140.
129. Cho CD, Fisher GA, Halsey J, and Sikic BI. Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies *Investigational New Drugs*, 24: 117-23, 2006. PMID: 16683204.
130. Kuo T, Cho CD, Halsey J, Wakelee HA, Advani RH, Ford JM, Fisher GA, and Sikic BI. A Phase II study of IFOX therapy (gefitinib, 5-fluorouracil, leucovorin, oxaliplatin) in previously treated patients with metastatic colorectal cancer. *J Clin Oncol*, 23: 5613-19, 2005. PMID: 16110021.
131. Bredel M, Bredel C, Juric D, Garsh GR, Vogel H, Recht LD, and Sikic BI. High-resolution genome-wide mapping of genetic alterations in human glial brain tumors. *Cancer Res*, 65: 4088-96, 2005. PMID: 15899798.
132. Chi KN, Chia SK, Dixon R, Newman MJ, Wachter VJ, Sikic BI, and Gelmon KA. A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer. *Investigational New Drugs*, 23: 311-315, 2005. PMID: 16012790.
133. Bredel M, Bredel C, Juric D, Harsh GR, Vogel H, Recht LD, and Sikic BI: Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas. *Cancer Res*, 65: 8679-89, 2005. PMID: 16204036.
134. Advani R, Lum BL, Fisher GA, Halsey J, Chin DL, Jacobs CD, and Sikic BI: A Phase I trial of liposomal doxorubicin, paclitaxel, and valspodar (PSC-833), an inhibitor of multidrug resistance. *Ann Oncol*, 16: 1968-73, 2005. PMID: 16126736.

135. Chen KG, Wang YC, Schaner ME, Francisco B, Duran GE, Juric D, Huff LM, Padilla-Nash H, Ried T, Fojo T, and Sikic BI: Genetic and epigenetic modeling of the origins of multidrug resistant cells in a human sarcoma cell line. *Cancer Res*, 65: 9388-97, 2005. PMID: 16230402.
136. Advani R, Lum B, Fisher G, Halsey J, Geary R, Holmlund J, Kwoh T, Dorr F, and Sikic B. A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C- $\alpha$  administered as a 24-hour weekly infusion schedule in patients with advanced cancer. *Investigational New Drugs*, 23: 467-477, 2005. PMID: 16133798.
137. Juric D, Sale S, Hromas RA, Yu R, Wang U, Duran GE, Tibshirani R, Einhorn LH, and Sikic BI: Molecular characterization of germ cell tumors by microarray gene expression profiling. *PNAS*, 102: 17763-68, 2005. PMCID: PMC1308932. PMID: 16306258.
138. Becton D, Dahl GV, Ravindranath Y, Chang MN, Behm FG, Raimondi SC, Head DR, Stine KC, Sikic BI, Arceci RJ, and Weinstein H. Randomized use of cyclosporine A (CSA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421. *Blood*, 107: 1315-24, 2006. PMCID: PMC1895393. PMID: 16254147.
139. Bredel M, Bredel C, Juric D, Duran GE, Yu RX, Harsh GR, Vogel H, Recht LD, Scheck AC, and Sikic BI: Tumor necrosis factor- $\alpha$ -induced protein 3 as a putative regulator of nuclear factor- $\kappa$ B-mediated resistance to O6-alkylating agents in human glioblastomas. *J Clin Oncol*, 24: 274-87, 2006. PMID: 16365179.
140. Wang YC, Juric D, Francisco B, Yu RX, Duran GE, Chen GK, Chen X, and Sikic BI: Regional activation of chromosome 7q with and without gene amplification in taxane-selected human ovarian carcinoma cell lines. *Genes Chromosomes Cancer*, 45: 365-74, 2006. PMID: 16382445.
141. DiMartino JF, Lacayo NJ, Varadi M, Li L, Saraiya C, Ravindranath Y, Yu R, Sikic BI, Raimondi SC, and Dahl GV: Low or absent SPARC expression in acute myeloid leukemia with *MLL* rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein. *Leukemia*, 20: 426-32, 2006. PMID: 16424866.
142. Carlson RW, O'Neill A, Goldstein L, Sikic BI, Abramson N, Steward JA, Davidson NE, and Wood, WC: A pilot Phase II trial of valspodar modulation of multidrug resistance to paclitaxel in the treatment of metastatic carcinoma of the breast (E1195): a trial of the Eastern Cooperative Oncology Group. *Cancer Investigation*, 24: 677-81, 2006. PMID: 17118777.
143. Kuo T, Fisher GA, and Sikic BI: Targeting EGFR with the IFOX regimen (gefitinib, 5-fluorouracil, leucovorin, oxaliplatin) in patients with previously treated metastatic colorectal cancer. *Am J Oncol Rev*, 2006.
144. Juric D, Lacayo NJ, Ramsey MC, Racevskis J, Wiernik PH, Rowe JM, Goldstone AH, O'Dwyer PJ, Paietta E, and Sikic BI: Differential gene expression patterns and interaction networks in BCR/ABL positive and negative adult acute lymphoblastic leukemias. *J Clin Oncol*, 25: 1341-9, 2007. PMID: 17312329.
145. Juric D, Bredel C, Sikic BI, Bredel M: Integrated high-resolution genome-wide analysis of gene dosage and gene expression in human brain tumors. *Methods Mol Biol* 377: 187-202, 2007. PMID: 17634618.
146. Chan JK, Ueda SM, Sugiyama V, Stave C, Shin JY, Monk BJ, Sikic BI, Osann K, and Kapp DS: An analysis of phase II biologic studies and subsequent phase III trials - what are the predictors for success? *J Clin Oncol*, 26: 1511-8, 2008. PMID: 18285603.
147. Fisher GA, Kuo T, Ramsey M, Schwartz E, Rouse RV, Cho CD, Halsey J, and Sikic BI: A Phase II Study of Gefitinib, 5-Fluorouracil, Leucovorin, and Oxaliplatin (IFOX) in Previously Untreated Patients with Metastatic Colorectal Cancer. *Clin Cancer Res* 14: 7074-9, 2008. PMCID: PMC2583341. PMID: 18981005.
148. Marcelletti JF, Multani PS, Lancet JE, Baer MR, and Sikic BI: Leukemic blast and natural killer cell P-glycoprotein function and inhibition in a clinical trial of zosuquidar infusion in acute myeloid leukemia. *Leukemia Res*, 33: 769-74, 2009. PMID: 18976810.

149. Lancet JE, Baer MR, Duran GE, List AF, Fielding R, Marcelletti JF, Multani PS, and Sikic BI: A Phase I Trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia. *Leukemia Res*, 33: 1055-61, 2009. PMID: 19108889.
150. Bredel M, Scholtens DM, Harsh GR, Bredel C, Chandler JP, Renfrow JJ, Yadav AK, Vogel H, Scheck AC, Tibshirani R, and Sikic BI: A network model of a cooperative genetic landscape in brain tumors. *JAMA*, 302: 261-75, 2009. PMID: 19602686.
151. Yadav AK, Renfrow JJ, Scholtens DM, Xie H, Duran GE, Bredel C, Vogel H, Chandler JP, Chakravarti A, Robe PA, Das S, Scheck AC, Kessler JA, Soares MB, Sikic BI, Harsh GR, and Bredel M: Monosomy of chromosome 10 associated with dysregulation of epidermal growth factor signaling in glioblastomas. *JAMA*, 302: 276-89, 2009. PMID: 19602687.
152. Wakelee HA, Patnaik A, Sikic BI, Mita M, Fox NL, Miceli R, Ullrich SJ, Fisher GA, and Tolcher AW: Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. *Ann Oncol*, 21: 376-81, 2010. PMID: 19633048.
153. O'Brien MM, Lacayo NJ, Lum BL, Kshirsagar S, Chin D, Buck S, Bernstein M, Weinstein H, Chang MN, Arceci RJ, Sikic BI, and Dahl GV: Phase I study of valsopodar (PSC 833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group. *Pediatr Blood Cancer*, 54: 694-702, 2010. PMID: 20209646.
154. Galatin, PS, Advani RH, Fisher GA, Francisco B, Julian T, Losa R, and Sikic BI: Phase I trial of oblimersen (Genasense) and gemcitabine in refractory and advanced malignancies. *Investigational New Drugs* 29: 971-7, 2011. PMID: 20349264.
155. Spicakova T, O'Brien MM, Duran GE, Sweet-Cordero A, and Sikic BI: Expression and silencing of microtubule-associated protein Tau in breast cancer cells. *Mol Cancer Ther* 9: 2970-81, 2010. PMID: 21062914.
156. Bredel M, Scholtens DM, Yadav AK, Alvarez A, Renfrow JJ, Chandler JP, Yu ILY, Carro MS, Dai F, Tagge MJ, Ferrarese R, Bredel C, Phillips HS, Lukac PJ, Robe PA, Weyerbrock A, Vogel H, Dubner S, Mobley B, He X, Scheck AC, Sikic BI, Aldape KD, Chakravarti A, Harsh GR: NFKBIA deletion in glioblastomas. *New Engl J Med* 364: 627-37, 2011. PMID: 21175304.
157. Cabebe EC, Fisher GA, and Sikic BI: A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer. *Investigational New Drugs* 30: 1082-7, 2012, [March 15, 2011, Epub ahead of print]. PMID: 21404105.
158. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. *Nature* 474: 609-615, 2011. PMID: 21720365.
159. Lai TL, Lavori P, Shih M-C, and Sikic BI: Clinical Trial Designs for testing biomarker-based personalized therapies. *Clin Trials* 9: 141-54, 2012. PMID: 22397801.
160. Kunz PL, He AR, Colevas AD, Pishvaian MJ, Hwang JJ, Clemens PL, Messina M, Kaleta R, Abrahao F, Sikic BI, and Marshall JL: Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors. *Investigational New Drugs* 2012, [February 16, 2012, Epub ahead of print]. PMID: 22331549.
161. Gevaert O, Villalobos V, Sikic BI, and Plevritis SK: Identification of ovarian cancer driver genes by using module network integration of multi-omics data. *Interface Focus* 3: 20130013, 2013. PMID: 24511378.
162. Moisan F, Francisco EB, Brozovic A, Duran GE, Wang YC, Chaturvedi S, Seethram S, Snyder LA, Doshi P, and Sikic BI: Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers. *Mol Oncol* 8, 1231-9, 2014. doi: 10.1016/j.molonc.2014.03.016. [Epub ahead of print, 2014 April 18]. PMID: 24816187.

163. Smith DC, Eisenberg PD, Manikhas G, Chugh R, Gubens MA, Stagg RJ, Kapoun AM, Xu L, Dupont J, and Sikic BI: A phase 1 dose escalation and expansion study of the anti-cancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors. *Clin Cancer Res*, 20: 6295-6303, 2014. Epub 2014 Oct 16. PMID: 25324140
164. Duran GE, Wang YC, Francisco EB, Rose JC, Martinez FJ, Coller J, Brassard D, Vrignaud P, and Sikic BI: Mechanisms of resistance to cabazitaxel. *Mol Cancer Therap*, 14: 193-201, 2015. Epub 2014 Nov 21. PMID: 25416788.
165. Brozovic A, Duran GE, Francisco EB, Wang YC, and Sikic BI: The miR-200 family regulates sensitivity to paclitaxel and carboplatin in human ovarian carcinoma OVCAR-3 and MES-OV cells. *Mol Oncol* 9: 1678-93, 2015. doi: 10.1016/j.molonc.2015.04.015. Epub 2015 May 16. PMID: 26025631.
166. Willis S, Villalobos VM, Gevaert O, Abramovitz M, Williams C, Sikic BI, Leyland-Jones B: Single gene prognostic biomarkers in ovarian cancer: a meta-analysis. *PLoS One*. 2016 Feb 17;11(2):e0149183. doi: 10.1371/journal.pone.0149183. eCollection 2016. PMID: 26886260.
167. Vrdoljak E, Bodoky G, Jassem J, Popescu RA, Mardiak J, Pirker R, Čufer T, Bešlija S, Eniu A, Todorović V, Kubáčková K, Kurteva G, Tomašević Z, Sallaku A, Smichkoska S, Bajić Ž, Sikic BI. Cancer Control in Central and Eastern Europe: Current Situation and Recommendations for Improvement. *Oncologist*. 2016 Jul 8. pii: theoncologist.2016-0137. [Epub ahead of print] PMID: 27401890.
168. Rosen LS, LoRusso P, Ma WW, Goldman JW, Weise A, Colevas AD, Adjei A, Yazji S, Shen A, Johnston S, Hsieh HJ, Chan IT, Sikic BI. A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors. *Invest New Drugs*. 2016 Oct;34(5):604-13. doi: 10.1007/s10637-016-0374-3. Epub 2016 Jul 16. PMID: 27424159.
169. Dubey R, Lebensohn AM, Bahrami-Nejad Z, Marceau C, Champion M, Gevaert O, Sikic BI, Carette JE, and Rohatgi R: Chromatin-remodeling complex SWI/SNF controls multidrug resistance by transcriptionally regulating the drug efflux pump ABCB1. *Cancer Res*, 76: 5810-21, 2016. Epub 2016 Aug 8. PMID: 27503929
170. Duran GE, Wang YC, Moisan F, Francisco EB, and Sikic BI: Decreased levels of baseline and drug-induced tubulin polymerization are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transition. *Br J Cancer*, 116: 1318-28, 2017. doi: 10.1038/bjc.2017.102. Epub 2017 Apr 11. PMID: 28399108
171. Burris HA, Infante JR, Ansell SM, Nemunaitis JJ, Weiss GR, Villalobos VM, Sikic BI, Taylor MH, Northfelt DW, Carson WE 3rd, Hawthorne TR, Davis TA, Yellin MJ, Keler T, and Bullock T: Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, in patients with advanced solid tumors. *J Clin Oncol*, 35: 2028-36, 2017. PMID: 28463630
172. Maio M, Lewis K, Demidov L, Mandalà M, Bondarenko I, Ascierto PA, Herbert C, Mackiewicz A, Rutkowski P, Guminski A, Goodman GR, Simmons B, Ye C, Yan Y, Schadendorf D; BRIM8 Investigators. Adjuvant vemurafenib in resected, BRAF<sup>v600</sup> mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. *Lancet Oncol*. 2018 Apr;19(4):510-520. doi: 10.1016/S1470-2045(18)30106-2. Epub 2018 Feb 21. Erratum in: *Lancet Oncol*. 2018 Apr;19(4):e184. PMID: 29477665
173. Duran GE, Derdau V, Weitz D, Philippe N, Blankenstein J, Atzrodt J, Sémiond D, Gianolio DA, Macé S, and Sikic BI. Cabazitaxel is more active than first-generation taxanes in ABCB1(+) cell lines due to its reduced affinity for P-glycoprotein. *Cancer Chemother Pharmacol*. 2018 Jun;81(6):1095-1103. doi: 10.1007/s00280-018-3572-1. Epub 2018 Apr 19. PMID: 29675746

174. Das M, Padda SK, Frymoyer A, Molina J, Adjei A, Lensing JL, Miles D, Sikic BI and Wakelee HA: XL-647: a safety, tolerability, and pharmacokinetic analysis of two Phase I studies of multitargeted, small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies. *Cancer Chemother Pharmacol*, 82: 541-550, 2018. PMID: 30030583
175. Vrdoljak E, Bodoky G, Jassem J, Popescu RA, Mardiak J, Perker R, Cufer T, Beslija S, Eniu A, Todorovic V, Kopeckova K, Kurteva G, Tomasevic Z, Sallaku A, Smichkoska S, Bajic Z, and Sikic, BI: Expenditures on oncology drugs and cancer mortality-to-incidence ratio in Central and Eastern Europe. *Oncologist*, 24: e30-e37, 2019. PMID: 30181313
176. Marcelletti JF, Sikic BI, Cripe LD, Paietta E. Evidence of a role for functional heterogeneity in multidrug resistance transporters in clinical trials of P-glycoprotein modulation in acute myeloid leukemia. *Cytometry B Clin Cytom*. 2019 Jan;96(1):57-66. doi: 10.1002/cyto.b.21737. Epub 2018 Oct 17. PMID: 30334334
177. Villalobos VM, Wang YC, Sikic BI. Reannotation and Analysis of Clinical and Chemotherapy Outcomes in the Ovarian Data Set from The Cancer Genome Atlas. *JCO Clin Cancer Inform*. 2018 Dec; 2:1-16. doi: 10.1200/CCI.17.00096. PMID: 30652548
178. Duran GE, Sikic BI. The Syk inhibitor R406 is a modulator of P-glycoprotein (ABCB1)-mediated multidrug resistance. *PLoS One*. 2019 Jan 22;14(1): e0210879. doi: 10.1371/journal.pone.0210879. eCollection 2019. PMID: 30668583
179. Sikic BI, Lakhani N, Patnaik A, Shah SA, Chandana SR, Rasco D, Colevas AD, O'Rourke T, Narayanan S, Papadopoulos K, Fisher GA, Villalobos V, Prohaska SS, Howard M, Beeram M, Chao MP, Agoram B, Chen JY, Huang J, Axt M, Liu J, Volkmer JP, Majeti R, Weissman IL, Takimoto CH, Supan D, Wakelee HA, Aoki R, Pegram MD, and Padda SK. First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients with Advanced Cancers. *J Clin Oncol*. 2019 Feb 27: JCO1802018. doi: 10.1200/JCO.18.02018. [Epub ahead of print] PMID: 30811285

#### Review Articles and Book Chapters:

1. Gram TE, Sikic BI, Litterst CL and Mimnaugh EG: Differential influence of physiological, pharmacological, and pathological alterations on hepatic and extrahepatic drug metabolism. In: *Microsomes and Drug Oxidations*, Ullrich V, Roots I, Hildebrandt A, Estrabrook R and Conney AH (Eds.), Pergamon Press, New York, 1977, pp. 527-533.
2. Sikic BI, Mimnaugh EG and Gram TE: Development of quantifiable parameters of bleomycin toxicity in the mouse lung. In: *Bleomycin: Current Status and New Developments*, Carter SK, Crooke S and Umezawa H (Eds.), Academic Press, New York, 1978, pp. 293-7.
3. Gram TE, Sikic BI, Litterst CL, Mimnaugh EG, Drew R and Siddik Z: The role of the lung in the metabolism and disposition of xenobiotics. In: *Industrial and Environmental Xenobiotics*, Fouts JR and Gut I (Eds.), Excerpta Medica, Amsterdam, 1978, pp. 53-58.
4. Sikic BI: Methyltransferases and drug metabolism. In: *Extra-hepatic Metabolism of Drugs and Other Foreign Compounds*, Gram TE (Ed.), Spectrum Publications, Inc., New York, 1980, pp. 533-549.
5. Sikic BI, Daniels JR, Chak L, Alexander M, Kohler M, and Carter SK: POCC versus POCC/VAM chemotherapy for small cell anaplastic (oat cell) lung cancer. In: *Nitrosoureas: Current Status and New Developments*, Baker L, Carter SK and Schein PS (Eds.), Academic Press, New York, 1981, pp. 221-231.
6. Sikic BI: The rational basis for cancer chemotherapy. In: *Modern Pharmacology*, Craig R and Stitzell R (Eds.), Little, Brown, and Co., 1982, pp. 745-756.
7. Sikic BI: Antineoplastic agents. In: *Modern Pharmacology*, Craig R and Stitzell R (Eds.), Little, Brown, and Co., 1982, pp. 757-790.

8. Muggia FM, Louie AC and Sikic BI: Pulmonary toxicity of antitumor agents. *Cancer Treat. Rev.* 10: 221-243, 1983.
9. Carlson RW and Sikic BI: Continuous infusion or bolus injection in cancer chemotherapy. *Ann. Intern. Med.* 99: 823-833, 1983.
10. Sikic BI, Chak LY, Daniels JR, Kohler M, and Carter SK: Alternating, non-cross-resistant chemotherapy of small cell lung cancer: a controlled trial from the Northern California Oncology Group. In: *Etoposide (VP-16): Current Status and New Developments*, Carter SK, Muggia F, and Issell BF (Eds.), Academic Press, New York, 1984, pp. 191-198.
11. Sikic BI and Carlson RW: Rate-controlled drug administration in cancer chemotherapy. In: *Rate Control in Drug Therapy*, Prescott LF, Nimmo WS (Eds.), Churchill Livingstone, Edinburgh, 1985, pp. 276-281.
12. Sikic BI: Clinical pharmacology of bleomycin. In: *Bleomycin Chemotherapy*, Sikic BI, Rozenzweig M, and Carter SK, (Eds.) Academic Press, New York, NY, 1985, pp. 37-43.
13. Ballon SC and Sikic BI: Bleomycin in cervical carcinoma: protocols of the Northern California Oncology Group. In: *Bleomycin Chemotherapy*, Sikic BI, Rozenzweig M, and Carter SK, (Eds.) Academic Press, New York, NY, 1985, pp. 239-244.
14. Carlson RW and Sikic BI: Effective treatment of malignant ovarian germ cell tumors with cisplatin, bleomycin and vinblastine (PVB). In: *Bleomycin Chemotherapy*, Sikic BI, Rozenzweig M, and Carter SK, (Eds.) Academic Press, New York, NY, 1985, pp. 69-76.
15. Sikic BI: Pulmonary toxicity of bleomycin. In: *Bleomycin Chemotherapy*, Sikic BI, Rozenzweig M, and Carter SK, (Eds.) Academic Press, New York, NY, 1985, pp. 247-254.
16. Sikic BI and Carlson RW: Effects of schedules of drug administration in cancer chemotherapy. In: *Rate-Controlled Drug Administration and Action*, Struyker-Boudier H (Ed.), CRC Press, Inc., Boca Raton, FL, 1985, pp. 205-219.
17. Sikic BI: The use of new drug delivery systems in clinical pharmacology. In: *Principles and Techniques of Human Research and Therapeutics*, McMahan FG (Ed.), Futura Publishing Co., Mt. Kisco, NY, 1985, pp. 51-62.
18. Sikic BI: The rational basis for cancer chemotherapy. In: *Modern Pharmacology*, Craig CR and Stitzell RE (Eds.), Little, Brown, and Co., Boston, MA, 2nd Edition, 1986, pp.784-796.
19. Sikic BI: Antineoplastic agents. In: *Modern Pharmacology*, Craig CR and Stitzell RE (Eds.), Little, Brown, and Co., Boston, MA, Second Edition, 1986, pp. 797-832.
20. Sikic BI: Antimetabolites and antineoplastics antibiotics. In: *Pharmacologic Aspects of Nursing*, Pagliaro AM and Pagliaro LA (Eds.), C. V. Mosby Co., St. Louis, MO, 1986, pp. 1139-1165.
21. Sikic BI: Alkylating agents and miscellaneous drugs used to treat cancer. In: *Pharmacologic Aspects of Nursing*, Pagliaro AM and Pagliaro LA (Eds.), C. V. Mosby Co., St. Louis, MO, 1986, pp. 1166-1192.
22. Sikic BI: Human tumor clonogenic assays: current status and potential future roles. In: *Fundamentals of Cancer Chemotherapy*, Carter SK and Hellman K (Eds.), McGraw-Hill Book Co., New York, NY, 1986, pp. 425-437.
23. Sikic BI: Theoretical, clinical, and pharmacokinetic aspects of cancer chemotherapy administered by continuous infusion. In: *Clinical Applications of Continuous Infusion Chemotherapy and Concomitant Radiation Therapy*, Rosenthal C and Rotman M, (Eds.), Plenum Publishing Corp., New York, NY, 1986, pp. 3-12.
24. Sikic BI: Anti-cancer drug sensitivity testing: Current role and future prospects. In: *Cancer Chemotherapy: Challenges for the Future*, Kimura K, Yamada K, Krakoff I, and Carter SK, (Eds.), Excerpta Medica, Ltd., Tokyo, 1986, pp. 48-57.

25. Sikic BI: Biochemical and cellular determinants of bleomycin cytotoxicity. *Cancer Surveys* 5: 81-91, 1986.
26. Schein PS, Allegra JC, Glick JH, Livingston RB, Macdonald JS, Sikic BI, and Woolley PV: Oncology Syllabus. In: *Medical Knowledge Self-Assessment Program VII*, American College of Physicians, Philadelphia, PA, 1986, pp. 283-321.
27. Sikic BI: Recent progress in the treatment of seminoma: the article reviewed. *Oncology*, 2: 26-30, 1988.
28. Lau DH, Yong-Sheng Z, and Sikic BI: Drug resistance in cancer chemotherapy. *Shantou Univ. J.*, 3: 113-118, 1988.
29. Sikic BI, Scudder SA, and Evans TL: Multidrug (pleiotropic) resistance in the human sarcoma cell line, MES-SA. In: *Resistance to Antineoplastic Drugs*, Kessel D (Ed.), CRC Press, Boca Raton, FL, 1989, pp. 37-47.
30. Sikic BI: Mechlorethamine. In: *Clinical Cancer Chemotherapy Handbook*, Armand JP, Droz JP, and Khoury S (Eds.), Fondation Internationale pour l'Information Scientifique, Paris, France, 1989, pp. 77-78.
31. Sikic BI: Bleomycin. In: *Clinical Cancer Chemotherapy Handbook*, Armand JP, Droz JP, and Khoury S (Eds.), Fondation Internationale pour l'Information Scientifique, Paris, France, 1989, pp.143-144.
32. Sikic BI: Antitumor antibiotics. *Current Opinion in Oncology*, 1: 198-202, 1989.
33. Sikic BI: The rational basis for cancer chemotherapy. In: *Modern Pharmacology*, Craig CR and Stitzell RE (Eds.), Little, Brown, and Co., Boston, MA, 3rd Edition, 1990, pp.776-786.
34. Sikic BI: Antineoplastic agents. In: *Modern Pharmacology*, Craig CR and Stitzell RE (Eds.), Little, Brown, and Co., Boston, MA, Third Edition, 1990, pp. 787-820.
35. Sikic BI: Combined chemotherapy and radiotherapy for advanced stage carcinomas of the cervix. In: *Radiation/Chemotherapy Interactions in Cancer Therapy*. Meyer JL and Vaeth JM (Eds.), S. Karger AG, Basel, Switzerland, 1992, pp. 153-161.
36. Kühl J-S, Sikic BI, Blume KG, and Chao NJ: Use of etoposide in combination with cyclosporine for purging multidrug resistant leukemic cells from bone marrow in a mouse model. In: *Advances in Bone Marrow Purging and Processing*. Worthington-White DA, Gee AP, and Gross S (Eds.), Wiley-Liss, Inc., New York, NY, 1992, pp. 25-34.
37. Lum BL, Gosland MP, Kaubisch S, and Sikic BI: Molecular targets in oncology: implications of the multidrug resistance gene. *Pharmacotherapy* 13: 88-109, 1993.
38. Fisher GA, Brophy NA, Yahanda AM, Adler KA, Lum BL, Bartlett NL, Halsey J, and Sikic BI: The modulation of multidrug resistance: Clinical studies at Stanford. In: *The Mechanism and New Approach on Drug Resistance of Cancer Cells*, Miyazaki T, Takaku F, and Sakurada K (Eds), Excerpta Medica, Amsterdam, 1993, pp 255-266.
39. Leyland-Jones B Dalton W, Fisher GA, and Sikic BI: Reversal of multidrug resistance to cancer chemotherapy. *Cancer* 72: 3484-3488, 1993.
40. Sikic BI: Multidrug resistance and its clinical relevance in acute leukemia: the article reviewed. *Oncology*, 1993
41. Dahl GV, Grier H, Sikic B, Weinstein H, and Arceci R: Multidrug resistance (MDR) reversal utilizing mitoxantrone, etoposide and continuous infusion cyclosporine (MEC) in pediatric ANLL. In: *Acute Leukemias - Prognostic Factors and Treatment Strategies*. Büchner et al. (Eds.) Springer-Verlag, Berlin, 1994, pp. 490-492.
42. Sikic BI: The rational basis for cancer chemotherapy. In: *Modern Pharmacology*, Craig CR and Stitzell RE (Eds.), Little, Brown, and Co., Boston, MA, Fourth Edition, 1994, pp. 663-672.



43. Sikic BI: Antineoplastic agents. In: *Modern Pharmacology*, Craig CR and Stitzell RE (Eds.), Little, Brown, and Co., Boston, MA, Fourth Edition, 1994, pp. 673-703.
44. Sikic BI, Fisher GA, Lum BL, Brophy NA, Yahanda AM, Adler KM, and Halsey J: Clinical reversal of multidrug resistance. In: *Anticancer Drug Resistance: Advances in Molecular and Clinical Research*. Goldstein L and Ozols R (Eds.). Kluwer Academic Publishers, Norwell, MA, 1994, pp. 149-165.
45. Yuen AR and Sikic BI: Multidrug resistance in lymphomas. *J. Clin. Oncol.* 12: 2453-2459, 1994.
46. Fisher GA and Sikic BI: Clinical studies with modulators of multidrug resistance. In: *Drug Resistance in Clinical Oncology and Hematology*. Fisher GA and Sikic BI (Eds.) Hematology/Oncology Clinics of North America, Vol. 9, No. 2. W. B. Saunders Co., Philadelphia, PA, 1995, pp. 363-382.
47. Fisher GA and Sikic BI: Drug resistance in clinical oncology and hematology: Preface. In: *Drug Resistance in Clinical Oncology and Hematology*. Fisher GA and Sikic BI (Eds.) Hematology/Oncology Clinics of North America, Vol. 9, No. 2. W. B. Saunders Co., Philadelphia, PA, 1995, pp. xi-xii.
48. Fisher GA, Lum BL, and Sikic BI: The reversal of multidrug resistance. In: *Concepts, Mechanisms, and New Targets for Chemotherapy*. Muggia FM (Ed.) Kluwer Academic Publishers, Boston, MA, 1995, pp. 45-70.
49. Dahl GV, Brophy N, Grier H, Weinstein H, Sikic B, and Arceci R: Mitoxantrone, etoposide, and cyclosporine A therapy for relapsed and refractory acute myelogenous leukemia, a Pediatric Oncology Group Phase II trial. In: *Acute Leukemias V - Experimental Approaches and Management of Refractory Disease*. Hiddeman W et al. (Eds.) Springer-Verlag, Berlin, 1996, pp.206-209.
50. Fisher GA, Lum BL, Hausdorff J, and Sikic BI: Pharmacological considerations in the modulation of multidrug resistance. *Eur. J. Cancer* 32A: 1082-1088, 1996.
51. Sikic BI: The rational basis for cancer chemotherapy. In: *Modern Pharmacology with Clinical Applications*, Craig CR and Stitzell RE (Eds.), Little, Brown, and Co., Boston, MA, Fifth Edition, 1997, pp. 659-666.
52. Sikic BI: Antineoplastic agents. In: *Modern Pharmacology with Clinical Applications*, Craig CR and Stitzell RE (Eds.), Little, Brown, and Co., Boston, MA, Fifth Edition, 1997, pp. 667-692.
53. Sikic BI: Pharmacologic approaches to reversing multidrug resistance. *Sem. Hematol.* 34 (Suppl.5): 40-47, 1997.
54. Advani R, Saba H, Tallman M, Rowe JM, Wiernik P, Ramek J, Dugan K, Litchman M, Sikic BI, Davis E, Paietta E, and Greenberg P: Treatment of poor prognosis acute myelogenous leukemia with PSC-833 and mitoxantrone, etoposide, cytarabine. In: *Acute Leukemias VII - Experimental Approaches and Management of Refractory Disease*. Hiddeman W et al. (Eds.) Springer-Verlag, Berlin, 1998, pp. 456-460.
55. Dumontet C and Sikic BI: Mechanisms of action of and resistance to anti-tubulin agents: microtubule dynamics, drug transport, and cell death. *J Clin Oncol* 17: 1061-1070, 1999.
56. Sikic BI: New approaches in cancer treatment. *Ann Oncol* 10: S149-S153, 1999.
57. Sikic BI and Berg D: Valspodar. In: *Outline of Oncology Therapeutics*. Ratain MJ, Tempero M, and Skosey C (Eds.). W. B. Saunders Co., Philadelphia, 2001, p. 78.
58. Lacayo NL, Baggott T, and Sikic BI: Pediatric chemotherapy. In: *Problems in Pediatric Drug Therapy*. Pagiaro LA and Pagliaro AM (Eds), American Pharmaceutical Association. Washington, DC, 2002, pp.493-529.

59. Sikic BI, Sebti SM, and Eckhardt SG: New agents and new targets. In: *American Society of Clinical Oncology 2002 Annual Meeting Summaries*, Johnson DH (Ed.), American Society of Clinical Oncology, Alexandria, VA, 2002, pp. 175-178.
60. Bredel M, Bredel C, and Sikic BI: Genomics-based hypothesis generation: a novel approach to unravelling drug resistance in brain tumors? *Lancet Oncol*, 5: 89-100, 2004.
61. Sikic BI: The rational basis for cancer chemotherapy. In: *Modern Pharmacology with Clinical Applications*, Craig CR and Stitzell RE (Eds.), Lippincott, Williams, and Wilkins, Philadelphia, PA, Sixth Edition, 2004, pp. 630-637.
62. Sikic BI: Antineoplastic agents. In: *Modern Pharmacology with Clinical Applications*, Craig CR and Stitzell RE (Eds.), Lippincott, Williams, and Wilkins, Philadelphia, PA, Sixth Edition, 2004, pp. 637-656.
63. Wakelee HA and Sikic BI. Activity of novel cytotoxic agents in lung cancer: epothilones and topoisomerase I inhibitors. *Clin Lung Cancer*, 7: S6-S12, 2005.
64. Moscow J, Schneider E, Sikic BI, Morrow CS, and Cowan KH: Drug resistance and its clinical circumvention. In: *Holland Frei - Cancer Medicine 7*, Kufe DW, Bast RC, Hait W, Hong WK, Pollock RE, Weichselbaum, RR, Holland JF, and Frei E, Eds., 7<sup>th</sup> Edition, BC Decker, Publisher, Hamilton, Ontario, Canada, pp. 630-647, 2006.
65. Sikic BI: Natural and acquired resistance to cancer therapies. In: *The Molecular Basis of Cancer* (Mendelsohn JH, Howley PM, Israel MA, Gray J, and Thompson CB Eds.), Third Edition, Elsevier, Philadelphia, PA, pp. 583-592, 2007.
66. Sikic BI: Modulation of classical multidrug resistance and drug resistance in general. In: *Innovative Leukemia and Lymphoma Therapy*, Kaspers GJL, Coiffier B, Heinrich MC, and Estey EH, Eds., Informa Healthcare USA, Inc., New York, NY, 2008.
67. Moscow J, Schneider E, Sikic BI, Morrow CS, and Cowan KH: Drug resistance and its clinical circumvention. In: *Holland Frei - Cancer Medicine*, Kufe DW, Bast RC, Hait W, Hong WK, Pollock RE, Weichselbaum, RR, Holland JF, and Frei E, Eds., Eighth Edition, BC Decker, Publisher, Hamilton, Ontario, Canada, Ch. 48, pp. 597-618, 2010.
68. Chen KG and Sikic BI: Molecular pathways: regulation and therapeutic implications of multidrug resistance. *Clin Cancer Res* 18: 1863-9, 2012. [February 16, 2012, Epub ahead of print]. PMID: 22344233.
69. Sikic BI: Natural and acquired resistance to cancer therapies. In: *The Molecular Basis of Cancer* (Mendelsohn JH, Gray JW, Howley PM, Israel MA, and Thompson CB, Eds.), Fourth Edition, Elsevier Saunders, Philadelphia, PA, Ch. 48, pp. 651-660, 2015.
70. Moscow J, Sikic BI, and Cowan KH: Drug resistance and its clinical circumvention. In: *Holland Frei - Cancer Medicine*, Bast RC, Croce CC, Hait W, Hong WK, Kufe DW, Pollock RE, Weichselbaum, RR, and Holland JF, Eds., Ninth Edition, BC Decker, Publisher, Hamilton, Ontario, Canada, In press.

#### Editorials and Letters:

1. Sikic BI and Taber RL: Human tumor clonogenic assays - an overview. *Cancer Chemother. Pharmacol.* 6: 201-203, 1981.
2. Sikic BI: Anticancer drug discovery. (Editorial) *J. Natl. Cancer Inst.* 83: 738-740, 1991.
3. Sikic BI: Modulation of multidrug resistance: at the threshold. (Editorial) *J. Clin. Oncol.* 11: 1629-1635, 1993.
4. Dalton WS and Sikic BI: The multidrug resistance gene (*mdr1*) represents a potential target for reversing drug resistance in human malignancies. (Controversies in Science: Multidrug Resistance). *J. NIH Res.* 6: 54-58, 1994.

5. Sikic BI: Modulation of multidrug resistance: a paradigm for translational clinical research. *Oncology* 5A: 183-187, 1999.
6. Sikic BI: Commentary on "Safety and Efficacy of the Multidrug Resistance Inhibitor Incel (Biricodar; VX-710) in Combination with Paclitaxel for Advanced Breast Cancer Refractory to Paclitaxel." *Breast Diseases: a Year Book Quarterly*, 2003.
7. Sikic BI: Combining EGFR inhibitors with chemotherapy. (Editorial). *Signal, the Journal of EGFR-Targeted Cancer Therapy* 5: 2-3, 2004.
8. Sikic BI: Multidrug resistance and stem cells in acute myeloid leukemia. [Editorial]. *Clin Cancer Res*, 12: 3231-2, 2006.
9. Sikic BI, Tibshirani R. and Lacayo NL: Genomics of childhood leukemia: the virtue of complexity. [Editorial]. *J Clin Oncol*, 26: 4367-8, 2008.
10. Sikic BI, Tibshirani R. and Lacayo NL: Reply to Catchpoole et al. [Letter]. *J Clin Oncol*, 28: in press, 2010.

**Books:**

1. Sikic BI, Rozenzweig M, and Carter SK, (Eds.) *Bleomycin Chemotherapy*, Academic Press, New York, NY, 1985.
2. Fisher GA and Sikic BI (Guest Eds.) *Drug Resistance in Clinical Oncology and Hematology*. In: *Hematology/Oncology Clinics of North America*, Vol. 9, No. 2. W. B. Saunders Co., Philadelphia, PA, 1995.